Teleflex (TFX) 10-Q 30 Apr 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 30, 2014	Apr. 21, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'TFX	'
Entity Registrant Name	'TELEFLEX INC	'
Entity Central Index Key	'0000096943	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	41,367,388

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 30, 2014	Mar. 31, 2013
Net revenues	$438,546	$411,877
Cost of goods sold	217,387	211,357
Gross profit	221,159	200,520
Selling, general and administrative expenses	140,297	126,950
Research and development expenses	14,062	15,007
Restructuring and other impairment charges	7,780	9,159
Income from continuing operations before interest and taxes	59,020	49,404
Interest expense	15,404	14,193
Interest income	-187	-157
Income from continuing operations before taxes	43,803	35,368
Taxes on income from continuing operations	8,534	7,667
Income from continuing operations	35,269	27,701
Operating loss from discontinued operations	-25	-758
Taxes (benefit) on loss from discontinued operations	100	-296
Loss from discontinued operations	-125	-462
Net income	35,144	27,239
Less: Income from continuing operations attributable to noncontrolling interest	186	201
Net income attributable to common shareholders	34,958	27,038
Basic:	'	'
Income from continuing operations	$0.85	$0.67
Loss from discontinued operations	'	($0.01)
Net income	$0.85	$0.66
Diluted:	'	'
Income from continuing operations	$0.77	$0.64
Loss from discontinued operations	($0.01)	($0.01)
Net income	$0.76	$0.63
Dividends per share	$0.34	$0.34
Weighted average common shares outstanding	'	'
Basic	41,262	41,014
Diluted	45,749	43,047
Amounts attributable to common shareholders:	'	'
Income from continuing operations, net of tax	35,083	27,500
Loss from discontinued operations, net of tax	-125	-462
Net income attributable to common shareholders	$34,958	$27,038

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 30, 2014	Mar. 31, 2013
Net income	$35,144	$27,239
Other comprehensive income (loss), net of tax:	'	'
Foreign currency translation, net of tax $3,189 and $(5,815)	4,117	-26,705
Pension and other postretirement benefit plans adjustment, net of tax of $503 and $504	624	1,090
Derivatives qualifying as hedges, net of tax $40 and $104	70	180
Other comprehensive income (loss), net of tax:	4,811	-25,435
Comprehensive income	39,955	1,804
Less: comprehensive income attributable to non-controlling interest	252	242
Comprehensive income attributable to common shareholders	$39,703	$1,562

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 30, 2014	Mar. 31, 2013
Foreign currency translation, tax	$3,189	($5,815)
Pension and other postretirement benefits plans adjustment, tax	503	504
Derivatives qualifying as hedges, tax	$40	$104

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets	'	'
Cash and cash equivalents	$421,649	$431,984
Accounts receivable, net	295,514	295,290
Inventories, net	349,745	333,621
Prepaid expenses and other current assets	47,543	39,810
Prepaid taxes	42,470	36,504
Deferred tax assets	51,983	52,917
Assets held for sale	11,714	10,428
Total current assets	1,220,618	1,200,554
Property, plant and equipment, net	328,679	325,900
Goodwill	1,372,058	1,354,203
Intangible assets, net	1,250,533	1,255,597
Investments in affiliates	1,513	1,715
Deferred tax assets	944	943
Other assets	67,789	70,095
Total assets	4,242,134	4,209,007
Current liabilities	'	'
Current borrowings	359,261	356,287
Accounts payable	71,094	71,967
Accrued expenses	79,455	74,868
Current portion of contingent consideration	1,658	4,131
Payroll and benefit-related liabilities	60,185	73,090
Accrued interest	9,066	8,725
Income taxes payable	27,451	23,821
Other current liabilities	23,637	22,231
Total current liabilities	631,807	635,120
Long-term borrowings	930,000	930,000
Deferred tax liabilities	523,445	514,715
Pension and postretirement benefit liabilities	106,092	109,498
Noncurrent liability for uncertain tax provisions	55,956	55,152
Other liabilities	49,607	48,506
Total liabilities	2,296,907	2,292,991
Commitments and contingencies	'	'
Total common shareholders' equity	1,942,486	1,913,527
Noncontrolling interest	2,741	2,489
Total equity	1,945,227	1,916,016
Total liabilities and equity	$4,242,134	$4,209,007

CONDENSED_CONSOLIDATED_STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 30, 2014	Mar. 31, 2013
Cash Flows from Operating Activities of Continuing Operations	'	'
Net income	$35,144	$27,239
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Loss from discontinued operations	125	462
Depreciation expense	11,580	10,153
Amortization expense of intangible assets	16,019	12,438
Amortization expense of deferred financing costs and debt discount	3,814	3,750
Changes in contingent consideration	-2,371	-1,193
Stock-based compensation	3,074	2,791
Deferred income taxes, net	3,515	-353
Other	-3,105	-7,415
Changes in operating assets and liabilities, net of effects of acquisitions and disposals:	'	'
Accounts receivable	5,966	-16,420
Inventories	-7,473	-13,693
Prepaid expenses and other current assets	-6,027	-435
Accounts payable and accrued expenses	-24,447	-13,199
Income taxes receivable and payable, net	-2,214	1,139
Net cash provided by operating activities from continuing operations	33,600	5,264
Cash Flows from Investing Activities of Continuing Operations:	'	'
Expenditures for property, plant and equipment	-12,109	-15,635
Proceeds from sale of assets and investments	1,669	'
Payments for businesses and intangibles acquired, net of cash acquired	-28,991	1,500
Investment in affiliates	-60	'
Net cash used in investing activities from continuing operations	-39,491	-14,135
Cash Flows from Financing Activities of Continuing Operations:	'	'
Proceeds and tax benefits from share based compensation plans	8,641	5,155
Debt extinguishment, issuance and amendment fees	-90	'
Payments for contingent consideration	'	-7,179
Dividends	-14,051	-13,964
Net cash used in financing activities from continuing operations	-5,500	-15,988
Cash Flows from Discontinued Operations:	'	'
Net cash used in operating activities	-1,167	-629
Net cash used in discontinued operations	-1,167	-629
Effect of exchange rate changes on cash and cash equivalents	2,223	-4,997
Net decrease in cash and cash equivalents	-10,335	-30,485
Cash and cash equivalents at the beginning of the period	431,984	337,039
Cash and cash equivalents at the end of the period	$421,649	$306,554

CONDENSED_CONSOLIDATED_STATEME4

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (USD $)	Total	Common Stock	Additional Paid in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Treasury Stock	Noncontrolling Interest
In Thousands, except Share data
Beginning Balance at Dec. 31, 2012	$1,781,537	$43,102	$394,384	$1,601,460	($132,048)	($127,948)	$2,587
Beginning Balance (in shares) at Dec. 31, 2012	'	43,102,000	'	'	'	2,130,000	'
Net income	27,239	'	'	27,038	'	'	201
Cash dividends ($0.34 per share)	-13,964	'	'	-13,964	'	'	'
Other comprehensive loss	-25,435	'	'	'	-25,476	'	41
Shares issued under compensation plans	5,654	79	3,173	'	'	2,402	'
Shares issued under compensation plans, shares	'	79,000	'	'	'	-49,000	'
Deferred compensation	46	'	-9	'	'	55	'
Deferred compensation, shares	'	'	'	'	'	-1,000	'
Ending Balance at Mar. 31, 2013	1,775,077	43,181	397,548	1,614,534	-157,524	-125,491	2,829
Ending Balance (in shares) at Mar. 31, 2013	'	43,181,000	'	'	'	2,080,000	'
Beginning Balance at Dec. 31, 2013	1,916,016	43,243	409,338	1,696,424	-110,855	-124,623	2,489
Beginning Balance (in shares) at Dec. 31, 2013	'	43,243,000	'	'	'	2,064,000	'
Net income	35,144	'	'	34,958	'	'	186
Cash dividends ($0.34 per share)	-14,051	'	'	-14,051	'	'	'
Other comprehensive loss	4,811	'	'	'	4,745	'	66
Shares issued under compensation plans	3,226	114	641	'	'	2,471	'
Shares issued under compensation plans, shares	'	114,000	'	'	'	-68,000	'
Deferred compensation	81	'	'	'	'	81	'
Deferred compensation, shares	'	'	'	'	'	-2,000	'
Ending Balance at Mar. 30, 2014	$1,945,227	$43,357	$409,979	$1,717,331	($106,110)	($122,071)	$2,741
Ending Balance (in shares) at Mar. 30, 2014	'	43,357,000	'	'	'	1,994,000	'

CONDENSED_CONSOLIDATED_STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) (USD $)	3 Months Ended
	Mar. 30, 2014	Mar. 31, 2013
Dividends per share	$0.34	$0.34

Basis_of_Presentation

Basis of Presentation	3 Months Ended
	Mar. 30, 2014
Basis of Presentation	'
	Note 1 — Basis of presentation
	We prepared the accompanying unaudited condensed consolidated financial statements of Teleflex Incorporated on the same basis as our annual consolidated financial statements.
	In the opinion of management, our financial statements reflect all adjustments, which are of a normal recurring nature, necessary for a fair presentation of financial statements for interim periods in accordance with U.S. generally accepted accounting principles (GAAP) and with Rule 10-01 of SEC Regulation S-X, which sets forth the instructions for financial statements included in Form 10-Q. The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our financial statements, as well as the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.
	In accordance with applicable accounting standards, the accompanying condensed consolidated financial statements do not include all of the information and footnote disclosures that are required to be included in our annual consolidated financial statements. The year-end condensed balance sheet data was derived from audited financial statements, but, as permitted by Rule 10-01 of SEC Regulation S-X, does not include all disclosures required by GAAP for complete financial statements. Accordingly, our quarterly condensed consolidated financial statements should be read in conjunction with the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2013.
	In June 2013, the Company revised its condensed consolidated statement of cash flows to reflect contingent consideration payments related to businesses acquired as a cash outflow from financing activities of continuing operations, thereby correcting a presentation error in previous filings. Prior to June 2013, these payments were reflected as a cash outflow from investing activities of continuing operations. Additionally, the Company has revised the condensed consolidated statements of cash flows, as well as the condensed consolidating statements of cash flows included in Note 15, for the three months ended March 31, 2013 to reclassify $7.2 million as cash outflow from financing activities to reflect this correction. The reclassifications resulting from the change were not considered material to any previously issued financial statements. The Company made certain additional revisions to the prior year condensed consolidating statements of cash flows included in the condensed consolidated guarantor financial information set forth in Note 15 to correct errors identified in the fourth quarter 2013.
	Effective January 1, 2014, the Company realigned its operating segments due to changes in the Company’s internal financial reporting structure. See Note 14 for additional information on the Company’s new reporting structure.
	As used in this report, the terms “we,” “us,” “our,” “Teleflex” and the “Company” mean Teleflex Incorporated and its subsidiaries, unless the context indicates otherwise. The results of operations for the periods reported are not necessarily indicative of those that may be expected for a full year.

New_Accounting_Standards

New Accounting Standards	3 Months Ended
	Mar. 30, 2014
New Accounting Standards	'
	Note 2 — New accounting standards
	From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date or, in some cases where early adoption is permitted, in advance of the specified effective date. The Company has assessed the recently issued standards that are not yet effective and believes these standards will not have a material impact on the Company’s results of operations, cash flows or financial position.

Acquisitions

Acquisitions	3 Months Ended
	Mar. 30, 2014
Acquisitions	'
	Note 3 — Acquisitions
	On February 3, 2014, the Company acquired Mayo Healthcare Pty Limited, (“Mayo” or “Mayo Healthcare”), a distributor of medical devices and supplies primarily in the Australian market. The total fair value of consideration for the Mayo acquisition was $28.5 million, which includes the initial payments of $29.0 million in cash, partially offset by a $0.5 million favorable working capital adjustment. Transaction expenses associated with the acquisition, which are included in selling, general and administrative expenses on the condensed consolidated statements of income, were $0.3 million for the three months ended March 30, 2014. The results of operations of the Mayo business are included in the condensed consolidated statements of income from the acquisition date. For the three months ended March 30, 2014, the Company recorded revenue and income from continuing operations before taxes of $4.1 million and $0.6 million, respectively, related to the Mayo business. Pro forma information is not presented as the Mayo operations are not significant to the overall operations of the Company.
	The following table presents the preliminary fair value determination of the assets acquired and liabilities assumed in the Mayo acquisition.
		(Dollars in thousands)
	Assets
	Current assets	$	24,287
	Property, plant and equipment		306
	Customer lists intangible asset		9,335
	Goodwill		15,986
	Total assets acquired		49,914
	Liabilities
	Current liabilities		18,595
	Deferred tax liabilities		2,800
	Liabilities assumed		21,395
	Net assets acquired	$	28,519
	The Company is continuing to evaluate the Mayo acquisition. Further adjustments to the fair value determination may be necessary as a result of the Company’s assessment of additional information related to the fair values of assets acquired and liabilities assumed, primarily with respect to deferred tax assets and liabilities and goodwill.
	Among the acquired assets, customer lists have a useful life of 10 years. The goodwill resulting from the acquisition primarily reflects the expected synergies of integrating the acquired business. Goodwill and the step-up in basis of the intangible assets in connection with stock acquisitions such as the Mayo acquisition are not deductible for tax purposes.
	The Company made the following acquisitions during 2013, all of which were accounted for as business combinations:
	·	On December 2, 2013, the Company acquired Vidacare Corporation, (“Vidacare”), a provider of intraosseous, or inside the bone, access devices. This acquisition complements the Company’s vascular access and specialty product portfolios.
	·	On June 11, 2013, the Company acquired the assets of Ultimate Medical Pty. Ltd. and its affiliates (“Ultimate”), a supplier of airway management devices and related products. This acquisition complements the Company’s anesthesia product portfolio.
	·	On June 6, 2013, the Company acquired Eon Surgical, Ltd. (“Eon”), a developer of a minimally invasive microlaparoscopy surgical platform technology designed to enhance a surgeon’s ability to perform scarless surgery while producing better patient outcomes. This technology complements the Company’s surgical product portfolio.
	The total fair value of consideration for the 2013 acquisitions is estimated at $307.0 million. The results of operations of the acquired businesses and assets are included in the consolidated statements of income from their respective acquisition dates. Pro forma information is not presented as the operations of the acquired businesses are not significant to the overall operations of the Company.

Restructuring_and_Other_Impair

Restructuring and Other Impairment Charges	3 Months Ended
	Mar. 30, 2014
Restructuring and Other Impairment Charges	'
	Note 4 — Restructuring and other impairment charges
	2014 European Restructuring Plan
	On February 27, 2014, the Company committed to a restructuring plan (the “2014 European Restructuring Plan”), which impacts certain administrative functions in Europe and will involve the consolidation of operations and a related reduction in workforce at certain of the Company’s European facilities. The plan was developed to further enhance the Company’s  competitive position.
	The Company estimates that it will record pre-tax charges of approximately $9.0 million in connection with implementing the 2014 European Restructuring Plan. Substantially all of these charges are expected to involve employee termination benefits and will result in future cash outlays. The Company incurred $8.3 million in charges related to termination benefits in the three month period ended March 30, 2014. As of March 30, 2014, the Company had a reserve of $6.6 million in connection with this project.  The Company expects to complete this program in 2014.
	As the program progresses, management will reevaluate the estimated costs set forth above, and may revise its estimates and the accounting charges relating thereto, as appropriate, consistent with generally accepted accounting principles.
	LMA Restructuring Program
	In connection with the acquisition of substantially all of the assets of LMA International N.V. (the “LMA business”) in 2012, the Company formulated a plan related to the integration of the LMA business and the Company’s other businesses. The integration plan focuses on the closure of the LMA business’ corporate functions and the consolidation of manufacturing, sales, marketing, and distribution functions in North America, Europe and Asia.
	A reconciliation of the changes in accrued liabilities associated with the LMA restructuring program from December 31, 2013 through March 30, 2014 is set forth in the following table:
		Termination Benefits			Facility Closure Costs			Contract Termination Costs			Other Restructuring Costs		Total
		(Dollars in thousands)
	Balance at December 31, 2013	$	552		$	427		$	3,686		$	16	$	4,681
	Subsequent accruals		—			42			(472	)		—		(430	)
	Cash payments		(276	)		(81	)		(144	)		—		(501	)
	Foreign currency translation		(1	)		—			(3	)		—		(4	)
	Balance at March 30, 2014	$	275		$	388		$	3,067		$	16	$	3,746
	During the three months ended March 30, 2014, the Company reversed approximately $0.5 million in contract termination costs related to a cancelled distributor agreement.
	Aside from nominal facility closure costs anticipated in 2014, the Company does not expect to incur additional costs associated with this program. The Company expects to complete the program in 2014.
	2013 Restructuring Charges
	In 2013, the Company initiated programs to consolidate manufacturing facilities in North America and warehouse facilities in Europe and terminate certain European distributor agreements in an effort to reduce costs. As a result of these actions, the Company estimates that it will incur an aggregate of up to $11.0 million in restructuring and other impairment charges over the term of these restructuring programs, of which $10.4 million was incurred through March 30, 2014. These programs entail costs related to reductions in force, contract termination costs and charges related to post-closing obligations associated with its acquired businesses. As of March 30, 2014, the Company has a reserve of $1.8 million in connection with these programs. The Company expects to complete this program in 2015.
	2012 Restructuring Charges
	In 2012, the Company identified opportunities to improve its supply chain strategy by consolidating its three North American warehouses into one centralized warehouse; and lower costs and improve operating efficiencies through the termination of certain distributor agreements in Europe, the closure of certain North American facilities and workforce reductions. These projects entail costs related to reductions in force, contract terminations related distributor agreements and leases, and facility closure and other costs. As of March 30, 2014, the Company has a reserve of $0.7 million in connection with these projects. The Company expects to complete this program in 2015.
	Impairment Charges
	In the first quarter 2013, the Company recorded a $4.5 million in-process research and development (IPR&D) charge pertaining to a research and development project associated with the acquisition of the assets of Axiom Technology Partners LLP because technological feasibility had not yet been achieved and the Company determined that the subject technology had no future alternative use.
	There were no impairment charges recorded for the three months ended March 30, 2014.
	The restructuring and other impairment charges recognized for the three months ended March 30, 2014 and March 31, 2013 consisted of the following:
	Three Months Ended March 30, 2014
	(in thousands)	Termination Benefits			Facility			Contract Termination			Other		Total
					Closure
					Costs
	LMA restructuring program	$	—		$	42		$	(472	)	$	—	$	(430	)
	2014 European restructuring plan		8,318			—			—			—		8,318
	2013 Restructuring charges		168			—			—			—		168
	2012 Restructuring charges		(610	)		320			—			—		(290	)
	2011 Restructuring plan		—			14			—			—		14
	Total restructuring and other impairment charges	$	7,876		$	376		$	(472	)	$	—	$	7,780
	Three Months Ended March 31, 2013
	(in thousands)	Termination Benefits			Facility			Contract Termination			Other		Total
					Closure
					Costs
	LMA restructuring program	$	2,024		$	81		$	442		$	108	$	2,655
	2013 Restructuring charges		421			—			—			59		480
	2012 Restructuring charges		1,450			—			—			—		1,450
	2007 Arrow integration program		—			80			—			—		80
			3,895			161			442			167		4,665
	Impairment charges		—			—			—			4,494		4,494
	Total restructuring and other impairment charges	$	3,895		$	161		$	442		$	4,661	$	9,159
	Termination benefits include employee severance and retention for terminated employees.
	Facility closure costs include general operating costs incurred subsequent to production shut-down as well as equipment relocation and other associated costs.
	Contract termination costs include costs associated with terminating existing leases and distributor agreements.
	Other costs include legal, outplacement and employee relocation costs and other employee-related costs.
	In the first quarter 2014, the Company changed its reporting structure to six reportable segments: Vascular North America, Anesthesia/Respiratory North America, Surgical North America, EMEA, Asia and OEM. See Note 14 for additional information on the Company’s new reporting structure.
	Restructuring and other impairment charges by reportable segment for the three months ended March 30, 2014 and March 31, 2013 are set forth in the following table:
		Three Months Ended
		30-Mar-14			31-Mar-13
		(Dollars in thousands)
	Restructuring and other impairment charges
	Vascular North America	$	14		$	497
	Anesthesia/Respiratory North America		27			1,906
	Surgical North America		—			4,494
	EMEA		7,889			1,294
	Asia		78			98
	All other		(228	)		870
	Total restructuring and other impairment charges	$	7,780		$	9,159

Inventories_Net

Inventories, Net	3 Months Ended
	Mar. 30, 2014
Inventories, Net	'
	Note 5 — Inventories, net
	Inventories as of March 30, 2014 and December 31, 2013 consisted of the following:
		March 30,			December 31,
		2014			2013
		(Dollars in thousands)
	Raw materials	$	72,047		$	70,209
	Work-in-process		57,632			53,672
	Finished goods		253,760			242,113
			383,439			365,994
	Less: Inventory reserve		(33,694	)		(32,373	)
	Inventories, net	$	349,745		$	333,621

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets, Net	3 Months Ended
	Mar. 30, 2014
Goodwill and other intangible assets, net	'
	Note 6 — Goodwill and other intangible assets, net
	In the first quarter of 2014, the Company changed its reporting structure to six reportable segments: Vascular North America, Anesthesia/Respiratory North America, Surgical North America, EMEA, Asia and OEM. See Note 14 for additional information on the Company’s new reporting structure.
	The following table provides information relating to changes in the carrying amount of goodwill by reportable segment for the three months ended March 30, 2014:
		Vascular			Anesthesia/			Surgical			EMEA			Asia		All			Total
																Other
		North America			Respiratory			North America
					North America
		(Dollars in thousands)
	Balance as of December 31, 2013
	Goodwill	$	474,044		$	167,195		$	250,506		$	373,417		$	136,946	$	284,223		$	1,686,331
	Accumulated impairment		(219,527	)		(107,073	)		—			—			—		(5,528	)		(332,128	)
	losses
			254,517			60,122			250,506			373,417			136,946		278,695			1,354,203
	Goodwill related to		—			—			—			—			15,986		—			15,986
	acquisitions
	Translation adjustment		—			(402	)		—			1,615			1,099		(443	)		1,869
	Balance as of March 30, 2014
	Goodwill		474,044			166,793			250,506			375,032			154,031		283,780			1,704,186
	Accumulated impairment		(219,527	)		(107,073	)		—			—			—		(5,528	)		(332,128	)
	losses
		$	254,517		$	59,720		$	250,506		$	375,032		$	154,031	$	278,252		$	1,372,058
	The following table provides information as of March 30, 2014 and December 31, 2013 regarding the gross carrying amount of, and accumulated amortization relating to, intangible assets, net:
		Gross Carrying Amount						Accumulated Amortization
		March 30,			December 31,			March 30,			December 31,
		2014			2013			2014			2013
		(Dollars in thousands)
	Customer relationships	$	638,476		$	628,020		$	(176,053	)	$	(168,223	)
	In-process research and development		68,786			68,786			—			—
	Intellectual property		436,189			435,869			(125,872	)		(118,086	)
	Distribution rights		16,863			16,797			(14,743	)		(14,592	)
	Trade names		408,375			407,879			(1,713	)		(1,148	)
	Noncompete agreements		337			337			(112	)		(42	)
		$	1,569,026		$	1,557,688		$	(318,493	)	$	(302,091	)
	During the first quarter 2013, the Company recorded an IPR&D charge of $4.5 million. See Note 4 for additional information.
	In May 2012, the Company acquired Semprus, a biomedical research and development company that developed a polymer surface treatment technology intended to reduce thrombus related complications.  The Company experienced unexpected difficulties with respect to the development of the Semprus technology, which the Company is currently attempting to resolve through further research and testing. Failure to resolve these issues may result in a reduction of the expected future cash flows related to the Semprus technology and could result in the recognition of impairment charges with respect to the related assets, which could be material.  As of March 30, 2014, the Company has recorded net assets of approximately $38 million related to this investment.
	Amortization expense related to intangible assets was $16.0 million and $12.4 million for the three months ended March 30, 2014 and March 31, 2013, respectively. Estimated annual amortization expense for the remainder of 2014 and the next five succeeding years is as follows (dollars in thousands):
	2014		$	49,100
	2015			55,500
	2016			54,500
	2017			54,000
	2018			53,500
	2019			51,000

Borrowings

Borrowings	3 Months Ended
	Mar. 30, 2014
Borrowings	'
	Note 7 — Borrowings
	The components of long-term debt at March 30, 2014 and December 31, 2013 are as follows:
			30-Mar-14			31-Dec-13
			(Dollars in thousands)
	Senior Credit Facility:
	Revolving credit facility, at a rate of 2.15% at March 30, 2014, due 7/16/2018		$	680,000		$	680,000
	3.875% Convertible Senior Subordinated Notes			400,000			400,000
	6.875% Senior Subordinated Notes due 2019			250,000			250,000
				1,330,000			1,330,000
	Less: Unamortized debt discount on 3.875% Convertible Senior Subordinated Notes			(45,439	)		(48,413	)
				1,284,561			1,281,587
	Current portion of borrowings			(354,561	)		(351,587	)
			$	930,000		$	930,000
	Convertible Notes
	The Company’s 3.875% Convertible Senior Subordinated Notes due 2017 (the “Convertible Notes”) are convertible under certain circumstances, including in any fiscal quarter following an immediately preceding fiscal quarter in which the last reported sales price of our common stock for at least 20 days during a period of 30 consecutive trading days ending on the last day of such fiscal quarter exceeds 130% of the conversion price of the notes (approximately $79.72). During the first quarter 2014 and the fourth quarter 2013, the Company’s closing stock price exceeded the 130% threshold described above and, accordingly, the Convertible Notes have been classified as a current liability as of March 30, 2014 and December 31, 2013. The determination of whether or not the Convertible Notes are convertible under such circumstances is made each quarter until maturity or conversion. Consequently, the Convertible Notes may not be convertible in one or more future quarters if the common stock price-based contingent conversion threshold is not met in such quarters, in which case the Convertible Notes would again be classified as long-term debt unless another conversion event set forth in the Convertible Notes has occurred. The Company has elected a net settlement method to satisfy our conversion obligation, under which it may settle the principal amount of the Convertible Notes in cash and settle the excess of the conversion value of the Convertible Notes over the principal amount of the notes in shares; however, cash will be paid in lieu of fractional shares. While the Company believes it has sufficient liquidity to repay the principal amounts due through a combination of its existing cash on hand and borrowings under its credit facility, the Company’s use of these funds could adversely affect our results of operations and liquidity. The classification of the Convertible Notes as a current liability had no impact on our financial covenants.
	Fair Value of Long-Term Debt
	The carrying amount of long-term debt reported in the consolidated balance sheet as of March 30, 2014 is $1,284.6 million. The Company uses a discounted cash flow technique that incorporates a market interest yield curve with adjustments for duration, optionality, and risk profile to determine the fair value of its debt. The Company’s implied credit rating is a factor in determining the market interest yield curve. The following table provides the fair value of the Company’s debt as of March 30, 2014, categorized by fair value hierarchy level (see Note 10, “Fair value measurement,” in the Company’s annual report on Form 10-K for the year ended December 31, 2013 for further information):
		Fair value of debt
		(Dollars in thousands)
	Level 1	$	969,595
	Level 2		653,209
	Total	$	1,622,804

Financial_Instruments

Financial Instruments	3 Months Ended
	Mar. 30, 2014
Financial Instruments	'
	Note 8 — Financial instruments
	The Company uses derivative instruments for risk management purposes. Forward rate contracts are used to manage foreign currency transaction exposure. These derivative instruments are designated as cash flow hedges and are recorded on the balance sheet at fair market value. The effective portion of the gains or losses on derivatives is reported as a component of other comprehensive income and thereafter is recognized in the condensed consolidated statement of income in the period or periods during which the hedged transaction affects earnings. Gains and losses on the derivatives representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings.
	The following table presents the location and fair values of derivative instruments designated as hedging instruments in the condensed consolidated balance sheet as of March 30, 2014 and December 31, 2013:
		March 30,			December 31,
		2014			2013
		Fair Value			Fair Value
		(Dollars in thousands)
	Asset derivatives:
	Foreign exchange contracts:
	Prepaid expenses and other current assets	$	684		$	—
	Total asset derivatives	$	684		$	—
	Liability derivatives:
	Foreign exchange contracts:
	Other current liabilities	$	493		$	—
	Total liability derivatives	$	493		$	—
	The total notional amount for all open contracts as of March 30, 2014 translates to approximately $68.8 million. As of December 31, 2013, the Company had no open forward rate contracts.
	The following table provides information as to the gains and losses attributable to derivatives in cash flow hedging relationships that were reported in other comprehensive income (“OCI”) for the three months ended March 30, 2014 and March 31, 2013:
		After Tax Gain/(Loss)
		Recognized in OCI
		March 30,			March 31,
		2014			2013
		(Dollars in thousands)
	Foreign exchange contracts	$	70		$	180
	Total	$	70		$	180
	See Note 10 for information on the location and amount of gains and losses attributable to derivatives that were reclassified from accumulated other comprehensive income (“AOCI”) to expense (income), net of tax.
	There was no ineffectiveness related to the Company’s derivatives used during the three months ended March 30, 2014 and March 31, 2013.
	Based on exchange rates at March 30, 2014, approximately $0.1 million of unrealized losses, net of tax, within AOCI are expected to be reclassified from AOCI to the condensed consolidated statement of income during the next year. However, the actual amount reclassified from AOCI could vary due to future changes in exchange rates.
	Concentration of Credit Risk
	Concentrations of credit risk with respect to trade accounts receivable is generally limited due to the Company’s large number of customers and their diversity across many geographic areas. A portion of the Company’s trade accounts receivable outside the United States, however, include sales to government-owned or supported healthcare systems in several countries which are subject to payment delays. Payment is dependent upon the financial stability and creditworthiness of those countries’ economies.
	In the ordinary course of business, the Company grants non-interest bearing trade credit to its customers on normal credit terms. In an effort to reduce its credit risk, the Company (i) establishes credit limits for all of its customer relationships, (ii) performs ongoing credit evaluations of its customers’ financial condition, (iii) monitors the payment history and aging of its customers’ receivables, and (iv) monitors open orders against an individual customer’s outstanding receivable balance.
	An allowance for doubtful accounts is maintained for accounts receivable based on the Company’s historical collection experience and expected collectability of the accounts receivable, considering the period an account is outstanding, the financial position of the customer and information provided by credit rating services. The adequacy of this allowance is reviewed each reporting period and adjusted as necessary.
	In light of the disruptions in global economic markets in recent years, the Company instituted enhanced measures, within countries where the Company has collectability concerns, to facilitate customer-by-customer risk assessment when estimating the allowance for doubtful accounts. Such measures included, among others, monthly credit control committee meetings, at which customer credit risks are identified after review of, among other things, accounts that exceed specified credit limits, payment delinquencies and other customer issues. In addition, for some of the Company’s non-government customers, the Company instituted measures designed to reduce its risk exposures, including issuing dunning letters, reducing credit limits, requiring that payments accompany orders and instituting legal action with respect to delinquent accounts. With respect to government customers, the Company evaluates receivables for potential collection risks associated with the availability of government funding and reimbursement practices.
	Some of the Company’s customers, particularly in Europe, have extended or delayed payments for products and services already provided. Collectability concerns regarding the Company’s accounts receivable from these customers, for the most part in Greece, Italy, Spain and Portugal, resulted in an increase in the allowance for doubtful accounts related to these countries. If the financial condition of these customers or the healthcare systems in these countries deteriorate such that the ability of an increasing number of customers to make payments is uncertain, additional allowances may be required in future periods. The aggregate net current and long-term accounts receivable for Spain, Italy, Greece and Portugal and the percentage of the Company’s net current and long-term accounts receivable represented by the net current and long-term accounts receivable in those countries at March 30, 2014 and December 31, 2013 are as follows:
		March 30,			December 31,
		2014			2013
		(Dollars in thousands)
	Current and long-term accounts receivable (net of allowances of $8.2 million and $7.9 million at March 30, 2014 and December 31, 2013, respectively) in Spain, Italy, Greece and Portugal(1)	$	97,885		$	97,852
	Percentage of total net current and long-term accounts receivable		32	%		31	%
	-1	The long-term portion of accounts receivable at March 30, 2014 and December 31, 2013 were $15.0 million and $17.6 million, respectively.
	For the three months ended March 30, 2014 and March 31, 2013, net revenues from customers in Spain, Italy, Greece and Portugal were $39.3 million and $37.2 million, respectively.

Fair_Value_Measurement

Fair Value Measurement	3 Months Ended
	Mar. 30, 2014
Fair Value Measurement	'
	Note 9 — Fair value measurement
	For a description of the fair value hierarchy, see Note 10 to the Company’s 2013 consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2013.
	The following tables provide information regarding the financial assets and liabilities measured at fair value on a recurring basis as of March 30, 2014 and December 31, 2013:
		Total carrying				Quoted prices in		Significant other		Significant
		value at				active markets		observable		unobservable
		March 30,				(Level 1)		Inputs (Level 2)		Inputs (Level 3)
		2014
		(Dollars in thousands)
	Investments in marketable securities	$	6,259			$	6,259	$	—	$	—
	Derivative assets		684				—		684		—
	Derivative liabilities		493				—		493		—
	Contingent consideration liabilities		17,942				—		—		17,942
		Total carrying				Quoted prices in		Significant other		Significant
		value at				active markets		observable		unobservable
		December 31, 2013				(Level 1)		Inputs (Level 2)		Inputs (Level 3)
		(Dollars in thousands)
	Investments in marketable securities	$	6,150			$	6,150	$	—	$	—
	Contingent consideration liabilities		20,313				—		—		20,313
	There were no transfers of financial assets or liabilities carried at fair value among Level 1, Level 2 or Level 3 within the fair value hierarchy during the three months ended March 30, 2014.
	The following table provides information regarding changes in Level 3 financial liabilities related to contingent consideration in connection with various Company acquisitions during the three months ended March 30, 2014:
		Contingent consideration
		2014
		(Dollars in thousands)
	Balance - December 31, 2013	$	20,313
	Revaluations		(2,371	)
	Balance - March 30, 2014	$	17,942
	The Company reduced contingent consideration liabilities and selling, general and administrative expense by $2.3 million for the three months ended March 30, 2014 as a result of delays encountered during the first quarter 2014 with respect to a product regulatory approval that will prevent the satisfaction of specified conditions related to the payment of certain contingent consideration.
	Valuation Techniques
	The Company’s financial assets valued based upon Level 1 inputs are comprised of investments in marketable securities held in trust, which are available to pay benefits under certain deferred compensation plans and other compensatory arrangements. The investment assets of the trust are valued using quoted market prices.
	The Company’s financial assets and financial liabilities valued based upon Level 2 inputs are comprised of foreign currency forward contracts. The Company uses forward rate contracts to manage currency transaction exposure. The fair value of the foreign currency forward exchange contracts represents the amount required to enter into offsetting contracts with similar remaining maturities based on quoted market prices. The Company has taken into account the creditworthiness of the counterparties in measuring fair value.
	The Company’s financial liabilities valued based upon Level 3 inputs are comprised of contingent consideration arrangements pertaining to the Company’s acquisitions. The Company accounts for contingent consideration in accordance with applicable accounting guidance related to business combinations. In connection with several of its acquisitions, the Company agreed to pay contingent consideration upon the achievement of specified objectives, including receipt of regulatory approvals, achievement of sales targets and, in some instances, the passage of time (collectively, “milestone payments”), and therefore recorded contingent consideration liabilities at the time of the acquisitions. The Company is required to reevaluate the fair value of contingent consideration each reporting period based on new developments and record changes in fair value until such consideration is satisfied through payment upon the achievement of the specified objectives or is no longer payable due to failure to achieve the specified objectives.
	It is estimated that milestone payments will occur in 2014 and may extend until 2018 or later. As of March 30, 2014, the range of undiscounted amounts the Company could be required to pay for contingent consideration arrangements is between zero and $61.0 million. The Company determines the fair value of the liabilities for the contingent consideration based on a probability-weighted discounted cash flow analysis. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the contingent consideration liability associated with future milestone payments was based on several factors including:
	—	estimated cash flows projected from the success of market launches;
	—	the estimated time and resources needed to complete the development of acquired technologies;
	—	the uncertainty of obtaining regulatory approvals within the required time periods; and
	—	the risk adjusted discount rate for fair value measurement.
	The following table provides information regarding the valuation techniques and inputs used in determining the fair value of assets or liabilities categorized as Level 3 measurements:
			Valuation Technique		Unobservable Input		Range (Weighted Average)
	Contingent consideration		Discounted cash flow		Discount rate		1%—10%(6%)
					Probability of payment		0%—100%(35%)
	As of March 30, 2014, of the $17.9 million of total recorded liabilities for contingent consideration, the Company has recorded approximately $1.7 million in Current portion of contingent consideration and the remaining $16.2 million in Other liabilities.

Changes_in_Shareholders_Equity

Changes in Shareholders' Equity	3 Months Ended
	Mar. 30, 2014
Changes in Shareholders' Equity	'
	Note 10 — Changes in shareholders’ equity
	In 2007, the Company’s Board of Directors authorized the repurchase of up to $300 million of outstanding Company common stock. Repurchases of Company stock under the Board authorization may be made from time to time in the open market and may include privately-negotiated transactions as market conditions warrant and subject to regulatory considerations. The stock repurchase program has no expiration date and the Company’s ability to execute on the program will depend on, among other factors, cash requirements for acquisitions, cash generated from operations, debt repayment obligations, market conditions and regulatory requirements. In addition, under the Company’s senior credit agreements, the Company is subject to certain restrictions relating to its ability to repurchase shares in the event the Company’s consolidated leverage ratio (generally, the ratio of Consolidated Total Indebtedness to Consolidated EBITDA, as defined in the senior credit agreements) exceeds certain levels, which may limit the Company’s ability to repurchase shares under this Board authorization. Through March 30, 2014, no shares have been purchased under this Board authorization.
	The following table provides a reconciliation of basic to diluted weighted average shares outstanding:
		Three Months Ended
		March 30, 2014			March 31, 2013
		(Shares in thousands)
	Basic		41,262			41,014
	Dilutive effect of share based awards		471			393
	Dilutive effect of 3.875% Convertible Notes and warrants		4,016			1,640
	Diluted		45,749			43,047
	Weighted average shares that were antidilutive and therefore not included in the calculation of earnings per share were approximately 6.5 million and 7.8 million for the three months ended March 30, 2014 and March 31, 2013, respectively.
	The Convertible Notes are included in the diluted net income per share calculation only during periods in which the average market price of our common stock was above the applicable conversion price of the Convertible Notes, or $61.32 per share, and, therefore, the impact of conversion would not be anti-dilutive. In these periods, under the treasury stock method, we calculate the number of shares issuable under the terms of the Convertible Notes based on the average market price of the stock during the period, and include that number in the total diluted shares outstanding for the period.
	In connection with the issuance of the Convertible Notes, the Company entered into convertible note hedge and warrant agreements. The convertible note hedge economically reduces the dilutive impact of the Convertible Notes. However, because applicable accounting guidance requires the Company to separately analyze the impact of the convertible note hedge agreements and the impact of the warrant agreements on diluted weighted average shares outstanding, the impact of the convertible note hedge agreements are excluded from the calculation of earnings per share because it would be anti-dilutive. The anti-dilutive shares associated with the convertible note hedges are 2.5 million and 1.4 million for the three months ended March 30, 2014 and March 31, 2013, respectively. The treasury stock method is applied when the warrants are in-the-money, assuming the proceeds from the exercise of the warrants are used to repurchase shares based on the average stock price during the period. The strike price of the warrants is approximately $74.65 per share of common stock. Shares issuable upon exercise of the warrants that were included in the total diluted shares outstanding were 1.6 million and 0.3 million for the three months ended March 30, 2014 and March 31, 2013, respectively.
	For additional information regarding the convertible notes and convertible note hedge and warrant agreements see Note 8 to the consolidated financial statements included in the Company’s annual report on Form 10-K for the year ended December 31, 2013.
	The following tables provide information relating to the changes in accumulated other comprehensive income (loss), net of tax, for the three months ended March 30, 2014 and March 31, 2013:
		Cash Flow Hedges			Pension and Other Postretirement Benefit Plans			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive Income (Loss)
		(Dollars in thousands)
	Balance at December 31, 2013	$	—		$	(97,037	)	$	(13,818	)	$	(110,855	)
	Other comprehensive income (loss)		113			(159	)		4,051			4,005
	before reclassifications
	Amounts reclassified from		(43	)		783			—			740
	accumulated other
	comprehensive  income (loss)
	Net current-period other		70			624			4,051			4,745
	comprehensive income
	Balance at March 30, 2014	$	70		$	(96,413	)	$	(9,767	)	$	(106,110	)
		Cash Flow Hedges			Pension and Other Postretirement Benefit Plans			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive Income (Loss)
		(Dollars in thousands)
	Balance at December 31, 2012	$	(381	)	$	(127,257	)	$	(4,410	)	$	(132,048	)
	Other comprehensive income (loss)		455			(365	)		(26,746	)		(26,656	)
	before reclassifications
	Amounts reclassified from		(275	)		1,455			—			1,180
	accumulated other
	comprehensive income (loss)
	Net current-period other		180			1,090			(26,746	)		(25,476	)
	comprehensive income (loss)
	Balance at March 31, 2013	$	(201	)	$	(126,167	)	$	(31,156	)	$	(157,524	)
	The following table provides information relating to the reclassifications of losses/(gain) in accumulated other comprehensive income into expense/(income), net of tax, for the three months ended March 30, 2014 and March 31, 2013:
		Three Months Ended
		March 30,			March 31,
		2014			2013
		(Dollars in thousands)
	Gains and losses on foreign exchange contracts:
	Cost of goods sold	$	(77	)	$	(502	)
	Total before tax		(77	)		(502	)
	Tax expense		34			227
	Net of tax	$	(43	)	$	(275	)
	Amortization of pension and other postretirement
	benefit items:
	Actuarial losses/(gains) (1)	$	1,102		$	2,145
	Prior-service costs(1)		(5	)		(6	)
	Transition obligation(1)		—			1
	Total before tax		1,097			2,140
	Tax expense		(314	)		(685	)
	Net of tax	$	783		$	1,455
	Total reclassifications, net of tax	$	740		$	1,180
	-1	These accumulated other comprehensive income components are included in the computation of net benefit cost of pension and other postretirement benefit plans (see Note 12 for additional information).

Taxes_on_Income_from_Continuin

Taxes on Income from Continuing Operations	3 Months Ended
	Mar. 30, 2014
Taxes on Income from Continuing Operations	'
	Note 11 — Taxes on income from continuing operations
		Three Months Ended
		March 30,			March 31,
		2014			2013
	Effective income tax rate		19.5	%		21.7	%
	The effective income tax rate for the three months ended March 30, 2014 was 19.5% compared to 21.7% for the three months ended March 31, 2013. The decrease in the effective tax rate for the three months ended March 30, 2014 is primarily attributable to a shift in the mix of taxable income to foreign jurisdictions that have lower statutory rates.

Pension_and_Other_Postretireme

Pension and Other Postretirement Benefits	3 Months Ended
	Mar. 30, 2014
Pension and Other Postretirement Benefits	'
	Note 12 — Pension and other postretirement benefits
	The Company has a number of defined benefit pension and postretirement plans covering eligible U.S. and non-U.S. employees. The defined benefit pension plans are noncontributory. The benefits under these plans are based primarily on years of service and employees’ pay near retirement. The Company’s funding policy for U.S. plans is to contribute annually, at a minimum, amounts required by applicable laws and regulations. Obligations under non-U.S. plans are systematically provided for by depositing funds with trustees or by book reserves. As of March 30, 2014 the Company’s U.S. defined benefit pension plans and the Company’s other postretirement benefit plans, except certain postretirement benefit plans covering employees subject to a collective bargaining agreement, are frozen.
	The Company and certain of its subsidiaries provide medical, dental and life insurance benefits to pensioners and survivors. The associated plans are unfunded and approved claims are paid from Company funds.
	Net benefit cost of pension and postretirement benefit plans consisted of the following:
		Pension						Other Postretirement Benefits
		Three Months Ended						Three Months Ended
		March 30,			March 31,			March 30,		March 31,
		2014			2013			2014		2013
		(Dollars in thousands)
	Service cost	$	450		$	465		$	138	$	164
	Interest cost		4,483			4,139			597		999
	Expected return on plan assets		(6,260	)		(5,770	)		—		—
	Net amortization and deferral		1,071			1,410			26		730
	Net benefit cost	$	(256	)	$	244		$	761	$	1,893
	The Company’s pension contributions are expected to be approximately $9.4 million during 2014, of which $2.4 million was made during the three months ended March 30, 2014.

Commitments_and_Contingent_lia

Commitments and Contingent liabilities	3 Months Ended
	Mar. 30, 2014
Commitments and Contingent Liabilities	'
	Note 13 — Commitments and contingent liabilities
	Operating leases: The Company uses various leased facilities and equipment in its operations. The terms for these leased assets vary depending on the terms of the applicable lease agreement. At March 30, 2014, the Company had no residual value guarantee obligations related to its operating leases.
	As of March 30 2014, the Company recorded $14.8 million in property, plant and equipment representing the estimated fair value of the Company’s percentage of the costs to construct a building under a build-to-suit lease. The build-to-suit lease was entered into in August 2013 and amended in March of 2014 and relates to a U.S. operating facility. Construction on the build-to-suit facility commenced in September 2013 and is expected to be completed in November 2014. The estimated fair value of the Company’s percentage of the construction costs to complete the build-to-suit lease is approximately $28.3 million. For accounting purposes, the Company is deemed the owner of the asset during the construction period and is required to record the estimated fair value of the Company’s percentage of the construction costs as construction in progress during the construction period and a related current liability in the same amount. These amounts do not reflect the Company’s cash obligations, but represent the landlord’s costs to construct the Company’s portion of the building and tenant improvements. Based on current expectations, the Company believes that there are no continuing involvement requirements that would prohibit the Company from derecognizing the assets and related liabilities upon commencement of the respective lease terms.
	Environmental: The Company is subject to contingencies as a result of environmental laws and regulations that in the future may require the Company to take further action to correct the effects on the environment of prior disposal practices or releases of chemical or petroleum substances by the Company or other parties. Much of this liability results from the U.S. Comprehensive Environmental Response, Compensation and Liability Act, often referred to as Superfund, the U.S. Resource Conservation and Recovery Act and similar state laws. These laws require the Company to undertake certain investigative and remedial activities at sites where the Company conducts or once conducted operations or at sites where Company-generated waste was disposed.
	Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, the regulatory agencies involved and their enforcement policies, as well as the presence or absence of other potentially responsible parties. At March 30, 2014, the Company has recorded $2.0 million in accrued liabilities and $5.5 million in other liabilities relating to these matters. Considerable uncertainty exists with respect to these liabilities and, if adverse changes in circumstances occur, the potential liability may exceed the amount accrued as of March 30, 2014. The time frame, over which the accrued amounts may be paid out, based on past history, is estimated to be 15-20 years.
	Litigation: The Company is a party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability, intellectual property, employment and environmental matters. As of March 30, 2014 and December 31, 2013, the Company has recorded reserves of approximately $3.9 million and $6.8 million, respectively, in connection with such contingencies, representing the best estimate of the cost within the range of estimated possible losses that will be incurred to resolve these matters. Based on information currently available, advice of counsel, established reserves and other resources, the Company does not believe that any such actions are likely to be, individually or in the aggregate, material to its business, financial condition, results of operations or liquidity. However, in the event of unexpected future developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to our business, financial condition, results of operations or liquidity.
	Tax audits and examinations: The Company and its subsidiaries are routinely subject to tax examinations by various taxing authorities. As of March 30, 2014, the most significant tax examinations in process are in Canada, the Czech Republic, Germany and Austria. In conjunction with these examinations and as a regular and routine practice, the Company may establish reserves or adjust existing reserves with respect to uncertain tax positions. Accordingly, developments occurring with respect to these examinations, including resolution of uncertain tax positions, could result in increases or decreases to the Company’s recorded tax liabilities, which could impact the Company’s financial results.
	Other: The Company has various purchase commitments for materials, supplies and items of permanent investment incident to the ordinary conduct of its business. On average, such commitments are not at prices in excess of current market prices.

Business_Segment_Information

Business Segment Information	3 Months Ended
	Mar. 30, 2014
Business Segment Information	'
	Note 14 — Business segment information
	An operating segment is a component of the Company (a) that engages in business activities from which it may earn revenues and incur expenses, (b) whose operating results are regularly reviewed by the Company’s chief operating decision maker to make decisions about resources to be allocated to the segment and to assess its performance, and (c) for which discrete financial information is available. The Company does not evaluate its operating segments using discrete asset information.
	Effective January 1, 2014, the Company realigned its operating segments due to changes in the Company’s internal financial reporting structure. The Company’s North American Vascular, Anesthesia/Respiratory and Surgical businesses, which previously comprised much of the former Americas reportable segment, are now separate reportable segments.  As a result, the Company now has six reportable segments: Vascular North America, Anesthesia/Respiratory North America, Surgical North America, EMEA, Asia and OEM. Certain operating segments are not material and are therefore included in the “All other” line item in tabular presentations of segment information. Additionally, the Company made changes to the allocation methodology of certain costs, including manufacturing variances and research and development costs, among the businesses to improve accountability, which resulted in changes to the previously reported segment profitability. All prior comparative periods have been restated to reflect these changes.
	The Company’s Vascular North America, Anesthesia/Respiratory North America, Surgical North America, EMEA and Asia reportable segments design, manufacture and distribute medical devices primarily used in critical care, surgical applications and cardiac care and generally serve two end markets: hospitals and healthcare providers, and home health. The products of these segments are most widely used in the acute care setting for a range of diagnostic and therapeutic procedures and in general and specialty surgical applications. The Company’s OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers.
	The following tables present the Company’s segment results for the three months ended March 30, 2014 and March 31, 2013:
		Three Months Ended
		March 30, 2014			March 31, 2013
		(Dollars in thousands)
	Revenue
	Vascular North America	$	62,506		$	56,674
	Anesthesia/Respiratory North America		54,714			58,174
	Surgical North America		35,231			36,688
	EMEA		150,245			142,418
	Asia		49,602			42,368
	OEM		33,182			31,338
	All other		53,066			44,217
	Consolidated net revenues	$	438,546		$	411,877
		Three Months Ended
		March 30, 2014			March 31, 2013
		(Dollars in thousands)
	Operating Profit
	Vascular North America	$	9,392		$	5,026
	Anesthesia/Respiratory North America		5,687			5,678
	Surgical North America		10,548			13,662
	EMEA		26,881			23,242
	Asia		12,837			12,096
	OEM		6,604			6,360
	All other		9,768			2,015
	Total segment operating profit (1)		81,717			68,079
	Unallocated expenses (2)		(22,697	)		(18,675	)
	Income from continuing operations before	$	59,020		$	49,404
	Interest and taxes
	-1	Segment operating profit includes segment net revenues from external customers reduced by its standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses.
	-2	Unallocated expenses primarily include manufacturing variances with the exception of fixed manufacturing cost absorption variances and restructuring and other impairment charges.
		Three Months Ended
		March 30, 2014			March 31, 2013
		(Dollars in thousands)
	Depreciation and Amortization
	Vascular North America	$	7,855		$	6,559
	Anesthesia/Respiratory North America		4,428			3,841
	Surgical North America		2,369			2,554
	EMEA		8,937			7,151
	Asia		1,838			1,212
	OEM		1,456			1,148
	All other		4,530			3,876
	Consolidated depreciation and amortization	$	31,413		$	26,341
	Geographic Data
	The following table provides total net revenues for the three months ended March 30, 2014 and March 31, 2013 and total net property, plant and equipment by geographic region as of March 30, 2014 and December 31, 2013:
		Three Months Ended
		March 30, 2014			March 31, 2013
		(Dollars in thousands)
	Net revenue (based on business unit location)
	United States	$	216,461		$	207,514
	Other Americas		14,771			14,151
	Germany		33,991			33,751
	Other Europe		134,784			106,686
	All other		38,539			49,775
		$	438,546		$	411,877
		30-Mar-14			31-Dec-13
		(Dollars in thousands)
	Net property, plant and equipment
	United States	$	203,005		$	203,985
	Other Americas		11,933			12,350
Germany		12,191			12,135
Other Europe		63,991			61,891
All other		37,559			35,539
	$	328,679		$	325,900

Condensed_Consolidated_Guarant

Condensed Consolidated Guarantor Financial Information	3 Months Ended
	Mar. 30, 2014
Condensed Consolidated Guarantor Financial Information	'
	Note 15 —Condensed consolidated guarantor financial information
	In June 2011, Teleflex Incorporated (referred to below as “Parent Company”) issued $250 million of 6.875% senior subordinated notes through a registered public offering. The notes are guaranteed, jointly and severally, by certain of the Parent Company’s subsidiaries (each, a “Guarantor Subsidiary” and collectively, the “Guarantor Subsidiaries”). The guarantees are full and unconditional, subject to certain customary release provisions. Each Guarantor Subsidiary is directly or indirectly 100% owned by the Parent Company. The Company’s condensed consolidating statements of income and comprehensive income (loss) for the three months ended March 30, 2014 and March 31, 2013, condensed consolidating balance sheets as of March 30, 2014 and December 31, 2013 and condensed consolidating statements of cash flows for the three months ended March 30, 2014 and March 31, 2013, provide consolidated information for:
	a.	Parent Company, the issuer of the guaranteed obligations;
	b.	Guarantor Subsidiaries, on a combined basis;
	c.	Non-guarantor subsidiaries, on a combined basis; and
	d.	Parent Company and its subsidiaries on a consolidated basis.
	The same accounting policies as described in Note 1 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 are used by the Parent Company and each of its subsidiaries in connection with the condensed consolidated financial information, except for the use by the Parent Company and Guarantor Subsidiaries of the equity method of accounting to reflect ownership interests in subsidiaries which are eliminated upon consolidation.
	Consolidating entries and eliminations in the following condensed consolidated financial statements represent adjustments to (a) eliminate intercompany transactions between or among the Parent Company, the Guarantor Subsidiaries and the Non-guarantor subsidiaries, (b) eliminate the investments in subsidiaries and (c) record consolidating entries.
	The Company adjusted the 2013 condensed consolidating statement of cash flows included within the guarantor financial information to correctly present dividends received from subsidiaries as an operating activity. The corrections had no impact on the consolidated financial information, but only resulted in reclassifications among the parent, guarantor subsidiaries, non-guarantor subsidiaries and eliminations. The Company does not consider the errors to be material to the previously issued consolidated financial statements.
	The following table illustrates the increase/(decrease) to the previously reported amounts as of March 31, 2013:
		Three Months Ended March 31, 2013
		Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
		Company			Subsidiaries			Subsidiaries						Consolidated
		(Dollars in thousands)
	Cash Flows from Operating Activities of Continuing	$	1,200		$	44,344		$	1,997		$	(47,541	)	$	—
	Operations
	Cash Flows from Financing Activities of Continuing
	Operations:
	Intercompany transactions		(1,200	)		(26,944	)		28,144			—			—
	Intercompany dividends paid		—			(17,400	)		(30,141	)		47,541			—
	Cash Flows from Financing Activities of Continuing	$	(1,200	)	$	(44,344	)	$	(1,997	)	$	47,541		$	—
	Operations
	The Company will also revise the previously reported interim condensed consolidating statements of cash flows for the six months ended June 30, 2013 and for the nine months ended September 29, 2013 when presented in future filings.
	TELEFLEX INCORPORATED AND SUBSIDIARIES
	CONDENSED CONSOLIDATING STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
		Three Months Ended March 30, 2014
		Parent			Guarantor			Non-Guarantor						Condensed
		Company			Subsidiaries			Subsidiaries			Eliminations			Consolidated
		(Dollars in thousands)
	Net revenues	$	-		$	262,425		$	248,437		$	(72,316	)	$	438,546
	Cost of goods sold		-			152,368			137,873			(72,854	)		217,387
	Gross profit		-			110,057			110,564			538			221,159
	Selling, general and administrative expenses		10,778			81,395			47,921			203			140,297
	Research and development expenses		-			12,010			2,052			-			14,062
	Restructuring and other impairment charges		-			(188	)		7,968			-			7,780
	Income (loss) from continuing operations before interest		(10,778	)		16,840			52,623			335			59,020
	and taxes
	Interest expense		33,726			(19,907	)		1,585			-			15,404
	Interest income		-			-			(187	)		-			(187	)
	Income (loss) from continuing operations before taxes		(44,504	)		36,747			51,225			335			43,803
	Taxes (benefit) on income (loss) from continuing		(15,420	)		17,218			8,832			(2,096	)		8,534
	operations
	Equity in net income of consolidated subsidiaries		64,124			43,108			94			(107,326	)		-
	Income from continuing operations		35,040			62,637			42,487			(104,895	)		35,269
	Operating loss from discontinued operations		(25	)		-			-			-			(25	)
	Taxes on loss from discontinued operations		57			-			43			-			100
	Loss from discontinued operations		(82	)		-			(43	)		-			(125	)
	Net income		34,958			62,637			42,444			(104,895	)		35,144
	Less: Income from continuing operations attributable to		-			-			186			-			186
	noncontrolling interests
	Net income attributable to common shareholders		34,958			62,637			42,258			(104,895	)		34,958
	Other comprehensive income attributable to common		4,745			7,228			8,523			(15,751	)		4,745
	shareholders
	Comprehensive income attributable to common	$	39,703		$	69,865		$	50,781		$	(120,646	)	$	39,703
	shareholders
		Three Months Ended March 31, 2013
		Parent			Guarantor			Non-Guarantor						Condensed
		Company			Subsidiaries			Subsidiaries			Eliminations			Consolidated
		(Dollars in thousands)
	Net revenues	$	-		$	254,856		$	230,805		$	(73,784	)	$	411,877
	Cost of goods sold		-			152,704			131,573			(72,920	)		211,357
	Gross profit		-			102,152			99,232			(864	)		200,520
	Selling, general and administrative expenses		16,928			67,156			42,672			194			126,950
Research and development expenses		-			13,007			2,000			-			15,007
Restructuring and other impairment charges		-			7,767			1,392			-			9,159
Income (loss) from continuing operations before interest		(16,928	)		14,222			53,168			(1,058	)		49,404
and taxes
Interest expense		33,535			(21,127	)		1,785			-			14,193
Interest income		(6	)		-			(151	)		-			(157	)
Income (loss) from continuing operations before taxes		(50,457	)		35,349			51,534			(1,058	)		35,368
Taxes (benefit) on income (loss) from continuing		(18,459	)		14,251			11,224			651			7,667
operations
Equity in net income of consolidated subsidiaries		59,820			34,150			-			(93,970	)		-
Income from continuing operations		27,822			55,248			40,310			(95,679	)		27,701
Operating income (loss) from discontinued operations		(1,126	)		-			368			-			(758	)
Taxes (benefit) on income (loss) from discontinued		(342	)		-			46			-			(296	)
operations
Income (loss) from discontinued operations		(784	)		-			322			-			(462	)
Net income		27,038			55,248			40,632			(95,679	)		27,239
Less: Income from continuing operations attributable to		-			-			201			-			201
noncontrolling interests
Net income attributable to common shareholders		27,038			55,248			40,431			(95,679	)		27,038
Other comprehensive loss attributable to common		(25,476	)		(32,126	)		(23,813	)		55,939			(25,476	)
shareholders
Comprehensive income attributable to common	$	1,562		$	23,122		$	16,618		$	(39,740	)	$	1,562
shareholders
TELEFLEX INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATING BALANCE SHEETS
	30-Mar-14
	Parent			Guarantor			Non-Guarantor						Condensed
	Company			Subsidiaries			Subsidiaries			Eliminations			Consolidated
	(Dollars in thousands)
ASSETS
Current assets
Cash and cash equivalents	$	22,211		$	5,513		$	393,925		$	-		$	421,649
Accounts receivable, net		1,282			8,528			282,435			3,269			295,514
Accounts receivable from consolidated subsidiaries		34,246			2,621,175			217,359			(2,872,780	)		-
Inventories, net		-			215,672			149,244			(15,171	)		349,745
Prepaid expenses and other current assets		15,252			6,542			25,749			-			47,543
Prepaid taxes		26,440			-			16,030			-			42,470
Deferred tax assets		20,178			20,346			11,463			(4	)		51,983
Assets held for sale		2,900			3,504			5,310			-			11,714
Total current assets		122,509			2,881,280			1,101,515			(2,884,686	)		1,220,618
Property, plant and equipment, net		2,787			198,893			126,999			-			328,679
Goodwill		-			797,671			574,387			-			1,372,058
Intangibles assets, net		-			949,082			301,451			-			1,250,533
Investments in affiliates		5,557,650			1,533,234			21,342			(7,110,713	)		1,513
Deferred tax assets		33,281			-			4,485			(36,822	)		944
Notes receivable and other amounts due from consolidated		1,240,228			1,543,569			1,149,117			(3,932,914	)		-
subsidiaries
Other assets		24,618			7,485			35,686			-			67,789
Total assets	$	6,981,073		$	7,911,214		$	3,314,982		$	(13,965,135	)	$	4,242,134
LIABILITIES AND EQUITY
Current liabilities
Current borrowings	$	354,561		$	-		$	4,700		$	-		$	359,261
Accounts payable		3,233			42,935			24,926			-			71,094
Accounts payable to consolidated subsidiaries		2,629,161			144,414			99,205			(2,872,780	)		-
Accrued expenses		15,064			19,821			44,570			-			79,455
Current portion of contingent consideration		-			1,658			-			-			1,658
Payroll and benefit-related liabilities		14,504			12,715			32,966			-			60,185
Accrued interest		9,061			-			5			-			9,066
Income taxes payable		-			-			27,451			-			27,451
Other current liabilities		493			18,465			4,683			(4	)		23,637
Total current liabilities		3,026,077			240,008			238,506			(2,872,784	)		631,807
Long-term borrowings		930,000			-			-			-			930,000
Deferred tax liabilities		-			497,911			62,356			(36,822	)		523,445
Pension and other postretirement benefit liabilities		53,955			33,642			18,495			-			106,092
Noncurrent liability for uncertain tax positions		11,962			17,313			26,681			-			55,956
Notes payable and other amounts due from consolidated subsidiaries		996,004			1,605,977			1,336,512			(3,938,493	)		-
Other liabilities		20,589			16,312			12,706			-			49,607
Total liabilities		5,038,587			2,411,163			1,695,256			(6,848,099	)		2,296,907
Total common shareholders' equity		1,942,486			5,500,051			1,616,985			(7,117,036	)		1,942,486
Noncontrolling interest		-			-			2,741			-			2,741
Total equity		1,942,486			5,500,051			1,619,726			(7,117,036	)		1,945,227
Total liabilities and equity	$	6,981,073		$	7,911,214		$	3,314,982		$	(13,965,135	)	$	4,242,134
	December 31, 2013
	Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
	Company			Subsidiaries			Subsidiaries						Consolidated
	(Dollars in thousands)
ASSETS
Current assets
Cash and cash equivalents	$	42,749		$	14,500		$	374,735		$	—		$	431,984
Accounts receivable, net		1,822			10,948			279,048			3,472			295,290
Accounts receivable from consolidated subsidiaries		42,865			2,623,314			214,469			(2,880,648	)		—
Inventories, net		—			211,165			138,165			(15,709	)		333,621
Prepaid expenses and other current assets		15,200			6,870			17,740			—			39,810
Prepaid taxes		27,487			—			9,017			—			36,504
Deferred tax assets		20,218			22,472			10,230			(3	)		52,917
Assets held for sale		1,669			3,503			5,256			—			10,428
Total current assets		152,010			2,892,772			1,048,660			(2,892,888	)		1,200,554
Property, plant and equipment, net		14,189			188,455			123,256			—			325,900
Goodwill		—			797,671			556,532			—			1,354,203
Intangibles assets, net		—			962,243			293,354			—			1,255,597
Investments in affiliates		5,489,676			1,478,429			21,382			(6,987,772	)		1,715
Deferred tax assets		35,877			—			4,476			(39,410	)		943
Notes receivable and other amounts due from		1,049,344			873,105			14,169			(1,936,618	)		—
consolidated subsidiaries
Other assets		24,574			7,447			38,074			—			70,095
Total assets	$	6,765,670		$	7,200,122		$	2,099,903		$	(11,856,688	)	$	4,209,007
LIABILITIES AND EQUITY
Current liabilities
Current borrowings	$	351,587		$	—		$	4,700		$	—		$	356,287
Accounts payable		2,194			45,802			23,971			—			71,967
Accounts payable to consolidated subsidiaries		2,644,296			147,957			88,395			(2,880,648	)		—
Accrued expenses		15,569			21,120			38,179			—			74,868
Current portion of contingent consideration		—			4,131			—			—			4,131
Payroll and benefit-related liabilities		15,976			21,818			35,296			—			73,090
Accrued interest		8,720			—			5			—			8,725
Income taxes payable		—			—			23,821			—			23,821
Other current liabilities		9,646			7,517			5,072			(4	)		22,231
Total current liabilities		3,047,988			248,345			219,439			(2,880,652	)		635,120
Long-term borrowings		930,000			—			—			—			930,000
Deferred tax liabilities		—			496,228			57,896			(39,409	)		514,715
Pension and other postretirement benefit liabilities		57,406			33,777			18,315			—			109,498
Noncurrent liability for uncertain tax positions		11,389			17,241			26,522			—			55,152
Notes payable and other amounts due from		785,476			957,451			197,173			(1,940,100	)		—
consolidated subsidiaries
Other liabilities		19,884			16,221			12,401			—			48,506
Total liabilities		4,852,143			1,769,263			531,746			(4,860,161	)		2,292,991
Total common shareholders' equity		1,913,527			5,430,859			1,565,668			(6,996,527	)		1,913,527
Noncontrolling interest		—			—			2,489			—			2,489
Total equity		1,913,527			5,430,859			1,568,157			(6,996,527	)		1,916,016
Total liabilities and equity	$	6,765,670		$	7,200,122		$	2,099,903		$	(11,856,688	)	$	4,209,007
TELEFLEX INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS
	Three Months Ended March 30, 2014
	Parent			Guarantor			Non-Guarantor						Condensed
	Company			Subsidiaries			Subsidiaries			Eliminations			Consolidated
	(Dollars in thousands)
Net cash (used in) provided by operating activities from continuing operations	$	(30,503	)	$	24,438		$	39,665		$	-		$	33,600
Cash Flows from Investing Activities of Continuing
Operations:
Expenditures for property, plant and equipment		(753	)		(4,823	)		(6,533	)		-			(12,109	)
Proceeds from sales of assets and investments		1,669			-			-			-			1,669
Payments for businesses and intangibles acquired, net of		-			-			(28,991	)		-			(28,991	)
cash acquired
Investments in affiliates		(60	)		-			-			-			(60	)
Net cash provided by (used in) investing activities from continuing		856			(4,823	)		(35,524	)		-			(39,491	)
operations
Cash Flows from Financing Activities of Continuing
Operations:
Proceeds and tax benefits from share based compensation plans		8,641			-			-			-			8,641
Debt issuance and amendment fees		(90	)		-			-			-			(90	)
Dividends		(14,051	)		-			-			-			(14,051	)
Intercompany transactions		15,776			(28,602	)		12,826			-			-
Net cash provided by (used in) financing activities from		10,276			(28,602	)		12,826			-			(5,500	)
continuing operations
Cash Flows from Discontinued Operations:
Net cash used in operating activities		(1,167	)		-			-			-			(1,167	)
Net cash used in discontinued operations		(1,167	)		-			-			-			(1,167	)
Effect of exchange rate changes on cash and cash		-			-			2,223			-			2,223
equivalents
Net (decrease) increase in cash and cash equivalents		(20,538	)		(8,987	)		19,190			-			(10,335	)
Cash and cash equivalents at the beginning of the period		42,749			14,500			374,735			-			431,984
Cash and cash equivalents at the end of the period	$	22,211		$	5,513		$	393,925		$	-		$	421,649
	Three Months Ended March 31, 2013
	Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
	Company			Subsidiaries			Subsidiaries						Consolidated
	(Dollars in thousands)
Net cash (used in) provided by operating activities from continuing operations	$	(37,035	)	$	64,415		$	25,425		$	(47,541	)	$	5,264
Cash Flows from Investing Activities of Continuing
Operations:
Expenditures for property, plant and equipment		(155	)		(12,129	)		(3,351	)		—			(15,635	)
Payments for businesses and intangibles acquired net of cash acquired		—			1,500			—			—			1,500
Net cash used in investing activities from continuing operations		(155	)		(10,629	)		(3,351	)		—			(14,135	)
Cash Flows from Financing Activities of Continuing
Operations:
Proceeds and tax benefits from share based compensation plans		5,155			—			—			—			5,155
Dividends		(13,964	)		—			—			—			(13,964	)
Payments for contingent consideration		—			(5,781	)		(1,398	)		—			(7,179	)
Intercompany transactions		22,271			(32,594	)		10,323			—			—
Intercompany dividends paid		—			(17,400	)		(30,141	)		47,541			—
Net cash provided by (used in) financing activities from continuing operations		13,462			(55,775	)		(21,216	)		47,541			(15,988	)
Cash Flows from Discontinued Operations:
Net cash used in operating activities		(29	)		—			(600	)		—			(629	)
Net cash used in discontinued operations		(29	)		—			(600	)		—			(629	)
Effect of exchange rate changes on cash and		—			—			(4,997	)		—			(4,997	)
cash equivalents
Net decrease in cash and cash equivalents		(23,757	)		(1,989	)		(4,739	)		—			(30,485	)
Cash and cash equivalents at the beginning of		70,860			1,989			264,190			—			337,039
the period
Cash and cash equivalents at the end of the	$	47,103		$	—		$	259,451		$	—		$	306,554
period

Subsequent_Event

Subsequent Event	3 Months Ended
	Mar. 30, 2014
Subsequent events	'
	Note 16 — Subsequent events
	2014 Restructuring Plan
	On April 28, 2014, the Board of Directors of Teleflex Incorporated (the “Company”) approved a restructuring plan (the “Plan”) designed to reduce costs, improve operating efficiencies and enhance the Company’s long-term competitive position.  The Plan, which was developed in response to continuing cost pressures in the healthcare industry, involves the consolidation of operations and a related reduction in workforce at certain of the Company’s facilities, and will include the relocation of manufacturing operations from certain higher-cost locations to existing lower-cost locations.  These actions will commence in the second quarter 2014 and are expected to be substantially completed by the end of 2017.
	The Company estimates that it will incur aggregate pre-tax charges in connection with these restructuring activities of approximately $42 million to $53 million, most of which are expected to be incurred prior to the end of 2016.  The Company estimates that $32 million to $40 million of the aggregate pre-tax charges will result in future cash outlays, most of which are expected to be incurred prior to the end of 2016.
	The following table provides a summary of the Company’s current cost estimates by major type of cost associated with the Plan:
		Total estimated amount expected to be incurred
	Type of cost
	Termination benefits	$12 million to $15 million
	Facility closure and other exit costs(1)	$2 million to $5 million
	Accelerated depreciation charges	$10 million to $12 million
	Other (2)	$18 million to $21 million
		$42 million to $53 million
	-1	Includes costs to transfer product lines among facilities and outplacement and employee relocation costs.
	-2	Consists of other costs directly related to the Plan, including project management, legal and other regulatory costs.
	As the Plan is implemented, management will continue to evaluate the estimated costs set forth above, and may revise its estimates of such costs and the accounting charges relating thereto, as appropriate, consistent with generally accepted accounting principles.
	Debt Repayment
	In April 2014, the Company repatriated $230 million of cash from its non-United States subsidiaries in connection with the integration of the Vidacare business into its existing organizational structure.  On April 28, 2014, the Company used the repatriated cash to partially fund a $235 million repayment of a portion of the outstanding principal amount of borrowings under its revolving credit facility.

Acquisitions_Tables

Acquisitions (Tables)	3 Months Ended
	Mar. 30, 2014
Fair Values Determination of Assets Acquired and Liabilities Assumed in Acquisition	'
	The following table presents the preliminary fair value determination of the assets acquired and liabilities assumed in the Mayo acquisition.
		(Dollars in thousands)
	Assets
	Current assets	$	24,287
	Property, plant and equipment		306
	Customer lists intangible asset		9,335
	Goodwill		15,986
	Total assets acquired		49,914
	Liabilities
	Current liabilities		18,595
	Deferred tax liabilities		2,800
	Liabilities assumed		21,395
	Net assets acquired	$	28,519

Restructuring_and_Other_Impair1

Restructuring and Other Impairment Charges (Tables)	3 Months Ended
	Mar. 30, 2014
Restructuring and Other Impairment Charges	'
	The restructuring and other impairment charges recognized for the three months ended March 30, 2014 and March 31, 2013 consisted of the following:
	Three Months Ended March 30, 2014
	(in thousands)	Termination Benefits			Facility			Contract Termination			Other		Total
					Closure
					Costs
	LMA restructuring program	$	—		$	42		$	(472	)	$	—	$	(430	)
	2014 European restructuring plan		8,318			—			—			—		8,318
	2013 Restructuring charges		168			—			—			—		168
	2012 Restructuring charges		(610	)		320			—			—		(290	)
	2011 Restructuring plan		—			14			—			—		14
	Total restructuring and other impairment charges	$	7,876		$	376		$	(472	)	$	—	$	7,780
	Three Months Ended March 31, 2013
	(in thousands)	Termination Benefits			Facility			Contract Termination			Other		Total
					Closure
					Costs
	LMA restructuring program	$	2,024		$	81		$	442		$	108	$	2,655
	2013 Restructuring charges		421			—			—			59		480
	2012 Restructuring charges		1,450			—			—			—		1,450
	2007 Arrow integration program		—			80			—			—		80
			3,895			161			442			167		4,665
	Impairment charges		—			—			—			4,494		4,494
	Total restructuring and other impairment charges	$	3,895		$	161		$	442		$	4,661	$	9,159
Reporting Segment	'
Restructuring and Other Impairment Charges	'
	Restructuring and other impairment charges by reportable segment for the three months ended March 30, 2014 and March 31, 2013 are set forth in the following table:
		Three Months Ended
		30-Mar-14			31-Mar-13
		(Dollars in thousands)
	Restructuring and other impairment charges
	Vascular North America	$	14		$	497
	Anesthesia/Respiratory North America		27			1,906
	Surgical North America		—			4,494
	EMEA		7,889			1,294
	Asia		78			98
	All other		(228	)		870
	Total restructuring and other impairment charges	$	7,780		$	9,159
LMA Restructuring Program	'
Changes in Accrued Liability Associated with Restructuring Program	'
	A reconciliation of the changes in accrued liabilities associated with the LMA restructuring program from December 31, 2013 through March 30, 2014 is set forth in the following table:
		Termination Benefits			Facility Closure Costs			Contract Termination Costs			Other Restructuring Costs		Total
		(Dollars in thousands)
	Balance at December 31, 2013	$	552		$	427		$	3,686		$	16	$	4,681
	Subsequent accruals		—			42			(472	)		—		(430	)
	Cash payments		(276	)		(81	)		(144	)		—		(501	)
	Foreign currency translation		(1	)		—			(3	)		—		(4	)
	Balance at March 30, 2014	$	275		$	388		$	3,067		$	16	$	3,746

Inventories_Net_Tables

Inventories, Net (Tables)	3 Months Ended
	Mar. 30, 2014
Inventories, Net	'
	Inventories as of March 30, 2014 and December 31, 2013 consisted of the following:
		March 30,			December 31,
		2014			2013
		(Dollars in thousands)
	Raw materials	$	72,047		$	70,209
	Work-in-process		57,632			53,672
	Finished goods		253,760			242,113
			383,439			365,994
	Less: Inventory reserve		(33,694	)		(32,373	)
	Inventories, net	$	349,745		$	333,621

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets, Net (Tables)	3 Months Ended
	Mar. 30, 2014
Changes in Carrying Amount of Goodwill, by Reporting Segment	'
	The following table provides information relating to changes in the carrying amount of goodwill by reportable segment for the three months ended March 30, 2014:
		Vascular			Anesthesia/			Surgical			EMEA			Asia		All			Total
																Other
		North America			Respiratory			North America
					North America
		(Dollars in thousands)
	Balance as of December 31, 2013
	Goodwill	$	474,044		$	167,195		$	250,506		$	373,417		$	136,946	$	284,223		$	1,686,331
	Accumulated impairment		(219,527	)		(107,073	)		—			—			—		(5,528	)		(332,128	)
	losses
			254,517			60,122			250,506			373,417			136,946		278,695			1,354,203
	Goodwill related to		—			—			—			—			15,986		—			15,986
	acquisitions
	Translation adjustment		—			(402	)		—			1,615			1,099		(443	)		1,869
	Balance as of March 30, 2014
	Goodwill		474,044			166,793			250,506			375,032			154,031		283,780			1,704,186
	Accumulated impairment		(219,527	)		(107,073	)		—			—			—		(5,528	)		(332,128	)
	losses
		$	254,517		$	59,720		$	250,506		$	375,032		$	154,031	$	278,252		$	1,372,058
Components of Intangible Assets	'
	The following table provides information as of March 30, 2014 and December 31, 2013 regarding the gross carrying amount of, and accumulated amortization relating to, intangible assets, net:
		Gross Carrying Amount						Accumulated Amortization
		March 30,			December 31,			March 30,			December 31,
		2014			2013			2014			2013
		(Dollars in thousands)
	Customer relationships	$	638,476		$	628,020		$	(176,053	)	$	(168,223	)
	In-process research and development		68,786			68,786			—			—
	Intellectual property		436,189			435,869			(125,872	)		(118,086	)
	Distribution rights		16,863			16,797			(14,743	)		(14,592	)
	Trade names		408,375			407,879			(1,713	)		(1,148	)
	Noncompete agreements		337			337			(112	)		(42	)
		$	1,569,026		$	1,557,688		$	(318,493	)	$	(302,091	)
Estimated Annual Amortization Expense	'
	Amortization expense related to intangible assets was $16.0 million and $12.4 million for the three months ended March 30, 2014 and March 31, 2013, respectively. Estimated annual amortization expense for the remainder of 2014 and the next five succeeding years is as follows (dollars in thousands):
	2014		$	49,100
	2015			55,500
	2016			54,500
	2017			54,000
	2018			53,500
	2019			51,000

Borrowings_Tables

Borrowings (Tables)	3 Months Ended
	Mar. 30, 2014
Components of Long-Term Debt	'
	The components of long-term debt at March 30, 2014 and December 31, 2013 are as follows:
			30-Mar-14			31-Dec-13
			(Dollars in thousands)
	Senior Credit Facility:
	Revolving credit facility, at a rate of 2.15% at March 30, 2014, due 7/16/2018		$	680,000		$	680,000
	3.875% Convertible Senior Subordinated Notes			400,000			400,000
	6.875% Senior Subordinated Notes due 2019			250,000			250,000
				1,330,000			1,330,000
	Less: Unamortized debt discount on 3.875% Convertible Senior Subordinated Notes			(45,439	)		(48,413	)
				1,284,561			1,281,587
	Current portion of borrowings			(354,561	)		(351,587	)
			$	930,000		$	930,000
Fair Value of Long-Term Debt	'
	The carrying amount of long-term debt reported in the consolidated balance sheet as of March 30, 2014 is $1,284.6 million. The Company uses a discounted cash flow technique that incorporates a market interest yield curve with adjustments for duration, optionality, and risk profile to determine the fair value of its debt. The Company’s implied credit rating is a factor in determining the market interest yield curve. The following table provides the fair value of the Company’s debt as of March 30, 2014, categorized by fair value hierarchy level (see Note 10, “Fair value measurement,” in the Company’s annual report on Form 10-K for the year ended December 31, 2013 for further information):
		Fair value of debt
		(Dollars in thousands)
	Level 1	$	969,595
	Level 2		653,209
	Total	$	1,622,804

Financial_Instruments_Tables

Financial Instruments (Tables)	3 Months Ended
	Mar. 30, 2014
Fair Values of Derivative Instruments Designated as Hedging Instruments	'
	The following table presents the location and fair values of derivative instruments designated as hedging instruments in the condensed consolidated balance sheet as of March 30, 2014 and December 31, 2013:
		March 30,			December 31,
		2014			2013
		Fair Value			Fair Value
		(Dollars in thousands)
	Asset derivatives:
	Foreign exchange contracts:
	Prepaid expenses and other current assets	$	684		$	—
	Total asset derivatives	$	684		$	—
	Liability derivatives:
	Foreign exchange contracts:
	Other current liabilities	$	493		$	—
	Total liability derivatives	$	493		$	—
After Tax Gain/(Loss) Recognized in OCI	'
	The following table provides information as to the gains and losses attributable to derivatives in cash flow hedging relationships that were reported in other comprehensive income (“OCI”) for the three months ended March 30, 2014 and March 31, 2013:
		After Tax Gain/(Loss)
		Recognized in OCI
		March 30,			March 31,
		2014			2013
		(Dollars in thousands)
	Foreign exchange contracts	$	70		$	180
	Total	$	70		$	180
Aggregate Accounts Receivable, Net of Allowance for Doubtful Accounts	'
	Some of the Company’s customers, particularly in Europe, have extended or delayed payments for products and services already provided. Collectability concerns regarding the Company’s accounts receivable from these customers, for the most part in Greece, Italy, Spain and Portugal, resulted in an increase in the allowance for doubtful accounts related to these countries. If the financial condition of these customers or the healthcare systems in these countries deteriorate such that the ability of an increasing number of customers to make payments is uncertain, additional allowances may be required in future periods. The aggregate net current and long-term accounts receivable for Spain, Italy, Greece and Portugal and the percentage of the Company’s net current and long-term accounts receivable represented by the net current and long-term accounts receivable in those countries at March 30, 2014 and December 31, 2013 are as follows:
		March 30,			December 31,
		2014			2013
		(Dollars in thousands)
	Current and long-term accounts receivable (net of allowances of $8.2 million and $7.9 million at March 30, 2014 and December 31, 2013, respectively) in Spain, Italy, Greece and Portugal(1)	$	97,885		$	97,852
	Percentage of total net current and long-term accounts receivable		32	%		31	%
	-1	The long-term portion of accounts receivable at March 30, 2014 and December 31, 2013 were $15.0 million and $17.6 million, respectively.

Fair_Value_Measurement_Tables

Fair Value Measurement (Tables)	3 Months Ended
	Mar. 30, 2014
Financial Assets and Liabilities Carried at Fair Value Measured on Recurring Basis	'
	The following tables provide information regarding the financial assets and liabilities measured at fair value on a recurring basis as of March 30, 2014 and December 31, 2013:
		Total carrying				Quoted prices in		Significant other		Significant
		value at				active markets		observable		unobservable
		March 30,				(Level 1)		Inputs (Level 2)		Inputs (Level 3)
		2014
		(Dollars in thousands)
	Investments in marketable securities	$	6,259			$	6,259	$	—	$	—
	Derivative assets		684				—		684		—
	Derivative liabilities		493				—		493		—
	Contingent consideration liabilities		17,942				—		—		17,942
		Total carrying				Quoted prices in		Significant other		Significant
		value at				active markets		observable		unobservable
		December 31, 2013				(Level 1)		Inputs (Level 2)		Inputs (Level 3)
		(Dollars in thousands)
	Investments in marketable securities	$	6,150			$	6,150	$	—	$	—
	Contingent consideration liabilities		20,313				—		—		20,313
Reconciliation of Changes in Level 3 Financial Liabilities Measured at Fair Value on Recurring Basis	'
	The following table provides information regarding changes in Level 3 financial liabilities related to contingent consideration in connection with various Company acquisitions during the three months ended March 30, 2014:
		Contingent consideration
		2014
		(Dollars in thousands)
	Balance - December 31, 2013	$	20,313
	Revaluations		(2,371	)
	Balance - March 30, 2014	$	17,942
Valuation Technique and Inputs Used to Determine Fair Value of Assets or Liabilities	'
	The following table provides information regarding the valuation techniques and inputs used in determining the fair value of assets or liabilities categorized as Level 3 measurements:
			Valuation Technique		Unobservable Input		Range (Weighted Average)
	Contingent consideration		Discounted cash flow		Discount rate		1%—10%(6%)
					Probability of payment		0%—100%(35%)

Changes_in_Shareholders_Equity1

Changes in Shareholders' Equity (Tables)	3 Months Ended
	Mar. 30, 2014
Reconciliation of Basic to Diluted Weighted Average Common Shares Outstanding	'
	The following table provides a reconciliation of basic to diluted weighted average shares outstanding:
		Three Months Ended
		March 30, 2014			March 31, 2013
		(Shares in thousands)
	Basic		41,262			41,014
	Dilutive effect of share based awards		471			393
	Dilutive effect of 3.875% Convertible Notes and warrants		4,016			1,640
	Diluted		45,749			43,047
Change in Accumulated Other Comprehensive Income (Loss)	'
	The following tables provide information relating to the changes in accumulated other comprehensive income (loss), net of tax, for the three months ended March 30, 2014 and March 31, 2013:
		Cash Flow Hedges			Pension and Other Postretirement Benefit Plans			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive Income (Loss)
		(Dollars in thousands)
	Balance at December 31, 2013	$	—		$	(97,037	)	$	(13,818	)	$	(110,855	)
	Other comprehensive income (loss)		113			(159	)		4,051			4,005
	before reclassifications
	Amounts reclassified from		(43	)		783			—			740
	accumulated other
	comprehensive  income (loss)
	Net current-period other		70			624			4,051			4,745
	comprehensive income
	Balance at March 30, 2014	$	70		$	(96,413	)	$	(9,767	)	$	(106,110	)
		Cash Flow Hedges			Pension and Other Postretirement Benefit Plans			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive Income (Loss)
		(Dollars in thousands)
	Balance at December 31, 2012	$	(381	)	$	(127,257	)	$	(4,410	)	$	(132,048	)
	Other comprehensive income (loss)		455			(365	)		(26,746	)		(26,656	)
	before reclassifications
	Amounts reclassified from		(275	)		1,455			—			1,180
	accumulated other
	comprehensive income (loss)
	Net current-period other		180			1,090			(26,746	)		(25,476	)
	comprehensive income (loss)
	Balance at March 31, 2013	$	(201	)	$	(126,167	)	$	(31,156	)	$	(157,524	)
Reclassification of Gain/Losses into Income/Expense, Net of Tax	'
	The following table provides information relating to the reclassifications of losses/(gain) in accumulated other comprehensive income into expense/(income), net of tax, for the three months ended March 30, 2014 and March 31, 2013:
		Three Months Ended
		March 30,			March 31,
		2014			2013
		(Dollars in thousands)
	Gains and losses on foreign exchange contracts:
	Cost of goods sold	$	(77	)	$	(502	)
	Total before tax		(77	)		(502	)
	Tax expense		34			227
	Net of tax	$	(43	)	$	(275	)
	Amortization of pension and other postretirement
	benefit items:
	Actuarial losses/(gains) (1)	$	1,102		$	2,145
	Prior-service costs(1)		(5	)		(6	)
	Transition obligation(1)		—			1
	Total before tax		1,097			2,140
	Tax expense		(314	)		(685	)
	Net of tax	$	783		$	1,455
	Total reclassifications, net of tax	$	740		$	1,180
	-1	These accumulated other comprehensive income components are included in the computation of net benefit cost of pension and other postretirement benefit plans (see Note 12 for additional information).

Taxes_on_Income_from_Continuin1

Taxes on Income from Continuing Operations (Tables)	3 Months Ended
	Mar. 30, 2014
Effective Income Tax Rate	'
		Three Months Ended
		March 30,			March 31,
		2014			2013
	Effective income tax rate		19.5	%		21.7	%

Pension_and_Other_Postretireme1

Pension and Other Postretirement Benefits (Tables)	3 Months Ended
	Mar. 30, 2014
Net Benefit Cost of Pension and Postretirement Benefit Plans	'
	Net benefit cost of pension and postretirement benefit plans consisted of the following:
		Pension						Other Postretirement Benefits
		Three Months Ended						Three Months Ended
		March 30,			March 31,			March 30,		March 31,
		2014			2013			2014		2013
		(Dollars in thousands)
	Service cost	$	450		$	465		$	138	$	164
	Interest cost		4,483			4,139			597		999
	Expected return on plan assets		(6,260	)		(5,770	)		—		—
	Net amortization and deferral		1,071			1,410			26		730
	Net benefit cost	$	(256	)	$	244		$	761	$	1,893

Business_Segment_Information_T

Business Segment Information (Tables)	3 Months Ended
	Mar. 30, 2014
Segment Results	'
	The following tables present the Company’s segment results for the three months ended March 30, 2014 and March 31, 2013:
		Three Months Ended
		March 30, 2014			March 31, 2013
		(Dollars in thousands)
	Revenue
	Vascular North America	$	62,506		$	56,674
	Anesthesia/Respiratory North America		54,714			58,174
	Surgical North America		35,231			36,688
	EMEA		150,245			142,418
	Asia		49,602			42,368
	OEM		33,182			31,338
	All other		53,066			44,217
	Consolidated net revenues	$	438,546		$	411,877
		Three Months Ended
		March 30, 2014			March 31, 2013
		(Dollars in thousands)
	Operating Profit
	Vascular North America	$	9,392		$	5,026
	Anesthesia/Respiratory North America		5,687			5,678
	Surgical North America		10,548			13,662
	EMEA		26,881			23,242
	Asia		12,837			12,096
	OEM		6,604			6,360
	All other		9,768			2,015
	Total segment operating profit (1)		81,717			68,079
	Unallocated expenses (2)		(22,697	)		(18,675	)
	Income from continuing operations before	$	59,020		$	49,404
	Interest and taxes
	-1	Segment operating profit includes segment net revenues from external customers reduced by its standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses.
	-2	Unallocated expenses primarily include manufacturing variances with the exception of fixed manufacturing cost absorption variances and restructuring and other impairment charges.
		Three Months Ended
		March 30, 2014			March 31, 2013
		(Dollars in thousands)
	Depreciation and Amortization
	Vascular North America	$	7,855		$	6,559
	Anesthesia/Respiratory North America		4,428			3,841
	Surgical North America		2,369			2,554
	EMEA		8,937			7,151
	Asia		1,838			1,212
	OEM		1,456			1,148
	All other		4,530			3,876
	Consolidated depreciation and amortization	$	31,413		$	26,341
Total Net Revenues and Total Net Property, Plant and Equipment by Geographic Region	'
	The following table provides total net revenues for the three months ended March 30, 2014 and March 31, 2013 and total net property, plant and equipment by geographic region as of March 30, 2014 and December 31, 2013:
		Three Months Ended
		March 30, 2014			March 31, 2013
		(Dollars in thousands)
	Net revenue (based on business unit location)
	United States	$	216,461		$	207,514
	Other Americas		14,771			14,151
	Germany		33,991			33,751
	Other Europe		134,784			106,686
	All other		38,539			49,775
		$	438,546		$	411,877
		30-Mar-14			31-Dec-13
		(Dollars in thousands)
	Net property, plant and equipment
	United States	$	203,005		$	203,985
	Other Americas		11,933			12,350
	Germany		12,191			12,135
	Other Europe		63,991			61,891
	All other		37,559			35,539
		$	328,679		$	325,900

Condensed_Consolidated_Guarant1

Condensed Consolidated Guarantor Financial Information (Tables)	3 Months Ended
	Mar. 30, 2014
Condensed Consolidating Financial Statement Adjustments	'
	The following table illustrates the increase/(decrease) to the previously reported amounts as of March 31, 2013:
		Three Months Ended March 31, 2013
		Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
		Company			Subsidiaries			Subsidiaries						Consolidated
		(Dollars in thousands)
	Cash Flows from Operating Activities of Continuing	$	1,200		$	44,344		$	1,997		$	(47,541	)	$	—
	Operations
	Cash Flows from Financing Activities of Continuing
	Operations:
	Intercompany transactions		(1,200	)		(26,944	)		28,144			—			—
	Intercompany dividends paid		—			(17,400	)		(30,141	)		47,541			—
	Cash Flows from Financing Activities of Continuing	$	(1,200	)	$	(44,344	)	$	(1,997	)	$	47,541		$	—
	Operations
Condensed Consolidating Statements of Income and Comprehensive Income (Loss)	'
	TELEFLEX INCORPORATED AND SUBSIDIARIES
	CONDENSED CONSOLIDATING STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
		Three Months Ended March 30, 2014
		Parent			Guarantor			Non-Guarantor						Condensed
		Company			Subsidiaries			Subsidiaries			Eliminations			Consolidated
		(Dollars in thousands)
	Net revenues	$	-		$	262,425		$	248,437		$	(72,316	)	$	438,546
	Cost of goods sold		-			152,368			137,873			(72,854	)		217,387
	Gross profit		-			110,057			110,564			538			221,159
	Selling, general and administrative expenses		10,778			81,395			47,921			203			140,297
	Research and development expenses		-			12,010			2,052			-			14,062
	Restructuring and other impairment charges		-			(188	)		7,968			-			7,780
	Income (loss) from continuing operations before interest		(10,778	)		16,840			52,623			335			59,020
	and taxes
	Interest expense		33,726			(19,907	)		1,585			-			15,404
	Interest income		-			-			(187	)		-			(187	)
	Income (loss) from continuing operations before taxes		(44,504	)		36,747			51,225			335			43,803
	Taxes (benefit) on income (loss) from continuing		(15,420	)		17,218			8,832			(2,096	)		8,534
	operations
	Equity in net income of consolidated subsidiaries		64,124			43,108			94			(107,326	)		-
	Income from continuing operations		35,040			62,637			42,487			(104,895	)		35,269
	Operating loss from discontinued operations		(25	)		-			-			-			(25	)
	Taxes on loss from discontinued operations		57			-			43			-			100
	Loss from discontinued operations		(82	)		-			(43	)		-			(125	)
	Net income		34,958			62,637			42,444			(104,895	)		35,144
	Less: Income from continuing operations attributable to		-			-			186			-			186
	noncontrolling interests
	Net income attributable to common shareholders		34,958			62,637			42,258			(104,895	)		34,958
	Other comprehensive income attributable to common		4,745			7,228			8,523			(15,751	)		4,745
	shareholders
	Comprehensive income attributable to common	$	39,703		$	69,865		$	50,781		$	(120,646	)	$	39,703
	shareholders
		Three Months Ended March 31, 2013
		Parent			Guarantor			Non-Guarantor						Condensed
		Company			Subsidiaries			Subsidiaries			Eliminations			Consolidated
		(Dollars in thousands)
	Net revenues	$	-		$	254,856		$	230,805		$	(73,784	)	$	411,877
	Cost of goods sold		-			152,704			131,573			(72,920	)		211,357
	Gross profit		-			102,152			99,232			(864	)		200,520
	Selling, general and administrative expenses		16,928			67,156			42,672			194			126,950
	Research and development expenses		-			13,007			2,000			-			15,007
	Restructuring and other impairment charges		-			7,767			1,392			-			9,159
	Income (loss) from continuing operations before interest		(16,928	)		14,222			53,168			(1,058	)		49,404
	and taxes
	Interest expense		33,535			(21,127	)		1,785			-			14,193
	Interest income		(6	)		-			(151	)		-			(157	)
	Income (loss) from continuing operations before taxes		(50,457	)		35,349			51,534			(1,058	)		35,368
	Taxes (benefit) on income (loss) from continuing		(18,459	)		14,251			11,224			651			7,667
	operations
	Equity in net income of consolidated subsidiaries		59,820			34,150			-			(93,970	)		-
	Income from continuing operations		27,822			55,248			40,310			(95,679	)		27,701
	Operating income (loss) from discontinued operations		(1,126	)		-			368			-			(758	)
	Taxes (benefit) on income (loss) from discontinued		(342	)		-			46			-			(296	)
	operations
	Income (loss) from discontinued operations		(784	)		-			322			-			(462	)
	Net income		27,038			55,248			40,632			(95,679	)		27,239
	Less: Income from continuing operations attributable to		-			-			201			-			201
	noncontrolling interests
	Net income attributable to common shareholders		27,038			55,248			40,431			(95,679	)		27,038
	Other comprehensive loss attributable to common		(25,476	)		(32,126	)		(23,813	)		55,939			(25,476	)
	shareholders
	Comprehensive income attributable to common	$	1,562		$	23,122		$	16,618		$	(39,740	)	$	1,562
	shareholders
Condensed Consolidating Balance Sheets	'
	TELEFLEX INCORPORATED AND SUBSIDIARIES
	CONDENSED CONSOLIDATING BALANCE SHEETS
		30-Mar-14
		Parent			Guarantor			Non-Guarantor						Condensed
		Company			Subsidiaries			Subsidiaries			Eliminations			Consolidated
		(Dollars in thousands)
	ASSETS
	Current assets
	Cash and cash equivalents	$	22,211		$	5,513		$	393,925		$	-		$	421,649
	Accounts receivable, net		1,282			8,528			282,435			3,269			295,514
	Accounts receivable from consolidated subsidiaries		34,246			2,621,175			217,359			(2,872,780	)		-
	Inventories, net		-			215,672			149,244			(15,171	)		349,745
	Prepaid expenses and other current assets		15,252			6,542			25,749			-			47,543
	Prepaid taxes		26,440			-			16,030			-			42,470
	Deferred tax assets		20,178			20,346			11,463			(4	)		51,983
	Assets held for sale		2,900			3,504			5,310			-			11,714
	Total current assets		122,509			2,881,280			1,101,515			(2,884,686	)		1,220,618
	Property, plant and equipment, net		2,787			198,893			126,999			-			328,679
	Goodwill		-			797,671			574,387			-			1,372,058
	Intangibles assets, net		-			949,082			301,451			-			1,250,533
	Investments in affiliates		5,557,650			1,533,234			21,342			(7,110,713	)		1,513
	Deferred tax assets		33,281			-			4,485			(36,822	)		944
	Notes receivable and other amounts due from consolidated		1,240,228			1,543,569			1,149,117			(3,932,914	)		-
	subsidiaries
	Other assets		24,618			7,485			35,686			-			67,789
	Total assets	$	6,981,073		$	7,911,214		$	3,314,982		$	(13,965,135	)	$	4,242,134
	LIABILITIES AND EQUITY
	Current liabilities
	Current borrowings	$	354,561		$	-		$	4,700		$	-		$	359,261
	Accounts payable		3,233			42,935			24,926			-			71,094
	Accounts payable to consolidated subsidiaries		2,629,161			144,414			99,205			(2,872,780	)		-
	Accrued expenses		15,064			19,821			44,570			-			79,455
	Current portion of contingent consideration		-			1,658			-			-			1,658
	Payroll and benefit-related liabilities		14,504			12,715			32,966			-			60,185
	Accrued interest		9,061			-			5			-			9,066
	Income taxes payable		-			-			27,451			-			27,451
	Other current liabilities		493			18,465			4,683			(4	)		23,637
	Total current liabilities		3,026,077			240,008			238,506			(2,872,784	)		631,807
	Long-term borrowings		930,000			-			-			-			930,000
	Deferred tax liabilities		-			497,911			62,356			(36,822	)		523,445
	Pension and other postretirement benefit liabilities		53,955			33,642			18,495			-			106,092
	Noncurrent liability for uncertain tax positions		11,962			17,313			26,681			-			55,956
	Notes payable and other amounts due from consolidated subsidiaries		996,004			1,605,977			1,336,512			(3,938,493	)		-
	Other liabilities		20,589			16,312			12,706			-			49,607
	Total liabilities		5,038,587			2,411,163			1,695,256			(6,848,099	)		2,296,907
	Total common shareholders' equity		1,942,486			5,500,051			1,616,985			(7,117,036	)		1,942,486
	Noncontrolling interest		-			-			2,741			-			2,741
	Total equity		1,942,486			5,500,051			1,619,726			(7,117,036	)		1,945,227
	Total liabilities and equity	$	6,981,073		$	7,911,214		$	3,314,982		$	(13,965,135	)	$	4,242,134
		December 31, 2013
		Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
		Company			Subsidiaries			Subsidiaries						Consolidated
		(Dollars in thousands)
	ASSETS
	Current assets
	Cash and cash equivalents	$	42,749		$	14,500		$	374,735		$	—		$	431,984
	Accounts receivable, net		1,822			10,948			279,048			3,472			295,290
	Accounts receivable from consolidated subsidiaries		42,865			2,623,314			214,469			(2,880,648	)		—
	Inventories, net		—			211,165			138,165			(15,709	)		333,621
	Prepaid expenses and other current assets		15,200			6,870			17,740			—			39,810
	Prepaid taxes		27,487			—			9,017			—			36,504
	Deferred tax assets		20,218			22,472			10,230			(3	)		52,917
	Assets held for sale		1,669			3,503			5,256			—			10,428
Total current assets		152,010			2,892,772			1,048,660			(2,892,888	)		1,200,554
Property, plant and equipment, net		14,189			188,455			123,256			—			325,900
Goodwill		—			797,671			556,532			—			1,354,203
Intangibles assets, net		—			962,243			293,354			—			1,255,597
Investments in affiliates		5,489,676			1,478,429			21,382			(6,987,772	)		1,715
Deferred tax assets		35,877			—			4,476			(39,410	)		943
Notes receivable and other amounts due from		1,049,344			873,105			14,169			(1,936,618	)		—
consolidated subsidiaries
Other assets		24,574			7,447			38,074			—			70,095
Total assets	$	6,765,670		$	7,200,122		$	2,099,903		$	(11,856,688	)	$	4,209,007
LIABILITIES AND EQUITY
Current liabilities
Current borrowings	$	351,587		$	—		$	4,700		$	—		$	356,287
Accounts payable		2,194			45,802			23,971			—			71,967
Accounts payable to consolidated subsidiaries		2,644,296			147,957			88,395			(2,880,648	)		—
Accrued expenses		15,569			21,120			38,179			—			74,868
Current portion of contingent consideration		—			4,131			—			—			4,131
Payroll and benefit-related liabilities		15,976			21,818			35,296			—			73,090
Accrued interest		8,720			—			5			—			8,725
Income taxes payable		—			—			23,821			—			23,821
Other current liabilities		9,646			7,517			5,072			(4	)		22,231
Total current liabilities		3,047,988			248,345			219,439			(2,880,652	)		635,120
Long-term borrowings		930,000			—			—			—			930,000
Deferred tax liabilities		—			496,228			57,896			(39,409	)		514,715
Pension and other postretirement benefit liabilities		57,406			33,777			18,315			—			109,498
Noncurrent liability for uncertain tax positions		11,389			17,241			26,522			—			55,152
Notes payable and other amounts due from		785,476			957,451			197,173			(1,940,100	)		—
consolidated subsidiaries
Other liabilities		19,884			16,221			12,401			—			48,506
Total liabilities		4,852,143			1,769,263			531,746			(4,860,161	)		2,292,991
Total common shareholders' equity		1,913,527			5,430,859			1,565,668			(6,996,527	)		1,913,527
Noncontrolling interest		—			—			2,489			—			2,489
Total equity		1,913,527			5,430,859			1,568,157			(6,996,527	)		1,916,016
Total liabilities and equity	$	6,765,670		$	7,200,122		$	2,099,903		$	(11,856,688	)	$	4,209,007
Condensed Consolidating Statements of Cash Flows	'
	TELEFLEX INCORPORATED AND SUBSIDIARIES
	CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS
		Three Months Ended March 30, 2014
		Parent			Guarantor			Non-Guarantor						Condensed
		Company			Subsidiaries			Subsidiaries			Eliminations			Consolidated
		(Dollars in thousands)
	Net cash (used in) provided by operating activities from continuing operations	$	(30,503	)	$	24,438		$	39,665		$	-		$	33,600
	Cash Flows from Investing Activities of Continuing
	Operations:
	Expenditures for property, plant and equipment		(753	)		(4,823	)		(6,533	)		-			(12,109	)
	Proceeds from sales of assets and investments		1,669			-			-			-			1,669
	Payments for businesses and intangibles acquired, net of		-			-			(28,991	)		-			(28,991	)
	cash acquired
	Investments in affiliates		(60	)		-			-			-			(60	)
	Net cash provided by (used in) investing activities from continuing		856			(4,823	)		(35,524	)		-			(39,491	)
	operations
	Cash Flows from Financing Activities of Continuing
	Operations:
	Proceeds and tax benefits from share based compensation plans		8,641			-			-			-			8,641
	Debt issuance and amendment fees		(90	)		-			-			-			(90	)
	Dividends		(14,051	)		-			-			-			(14,051	)
	Intercompany transactions		15,776			(28,602	)		12,826			-			-
	Net cash provided by (used in) financing activities from		10,276			(28,602	)		12,826			-			(5,500	)
	continuing operations
	Cash Flows from Discontinued Operations:
	Net cash used in operating activities		(1,167	)		-			-			-			(1,167	)
	Net cash used in discontinued operations		(1,167	)		-			-			-			(1,167	)
	Effect of exchange rate changes on cash and cash		-			-			2,223			-			2,223
	equivalents
	Net (decrease) increase in cash and cash equivalents		(20,538	)		(8,987	)		19,190			-			(10,335	)
	Cash and cash equivalents at the beginning of the period		42,749			14,500			374,735			-			431,984
	Cash and cash equivalents at the end of the period	$	22,211		$	5,513		$	393,925		$	-		$	421,649
		Three Months Ended March 31, 2013
		Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
		Company			Subsidiaries			Subsidiaries						Consolidated
		(Dollars in thousands)
	Net cash (used in) provided by operating activities from continuing operations	$	(37,035	)	$	64,415		$	25,425		$	(47,541	)	$	5,264
	Cash Flows from Investing Activities of Continuing
	Operations:
	Expenditures for property, plant and equipment		(155	)		(12,129	)		(3,351	)		—			(15,635	)
	Payments for businesses and intangibles acquired net of cash acquired		—			1,500			—			—			1,500
	Net cash used in investing activities from continuing operations		(155	)		(10,629	)		(3,351	)		—			(14,135	)
	Cash Flows from Financing Activities of Continuing
	Operations:
	Proceeds and tax benefits from share based compensation plans		5,155			—			—			—			5,155
	Dividends		(13,964	)		—			—			—			(13,964	)
	Payments for contingent consideration		—			(5,781	)		(1,398	)		—			(7,179	)
	Intercompany transactions		22,271			(32,594	)		10,323			—			—
	Intercompany dividends paid		—			(17,400	)		(30,141	)		47,541			—
	Net cash provided by (used in) financing activities from continuing operations		13,462			(55,775	)		(21,216	)		47,541			(15,988	)
	Cash Flows from Discontinued Operations:
	Net cash used in operating activities		(29	)		—			(600	)		—			(629	)
	Net cash used in discontinued operations		(29	)		—			(600	)		—			(629	)
	Effect of exchange rate changes on cash and		—			—			(4,997	)		—			(4,997	)
	cash equivalents
	Net decrease in cash and cash equivalents		(23,757	)		(1,989	)		(4,739	)		—			(30,485	)
	Cash and cash equivalents at the beginning of		70,860			1,989			264,190			—			337,039
	the period
	Cash and cash equivalents at the end of the	$	47,103		$	—		$	259,451		$	—		$	306,554
	period

Subsequent_Events_Tables

Subsequent Events (Tables)	3 Months Ended
	Mar. 30, 2014
Summary of Current Cost Estimates by Major Type of Cost Associated with Plan	'
	The following table provides a summary of the Company’s current cost estimates by major type of cost associated with the Plan:
		Total estimated amount expected to be incurred
	Type of cost
	Termination benefits	$12 million to $15 million
	Facility closure and other exit costs(1)	$2 million to $5 million
	Accelerated depreciation charges	$10 million to $12 million
	Other (2)	$18 million to $21 million
		$42 million to $53 million
	-1	Includes costs to transfer product lines among facilities and outplacement and employee relocation costs.
	-2	Consists of other costs directly related to the Plan, including project management, legal and other regulatory costs.

Basis_of_Presentation_Addition

Basis of Presentation - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2013
Organization And Summary Of Significant Accounting Policies Disclosure [Line Items]	'
Contingent consideration payments	$7,179
Reclassifications	'
Organization And Summary Of Significant Accounting Policies Disclosure [Line Items]	'
Contingent consideration payments	$7,200

Acquisitions_Additional_Inform

Acquisitions - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 30, 2014	Mar. 31, 2013	Dec. 31, 2013
Business Acquisition [Line Items]	'	'	'
Fair value of the consideration at the date of acquisition	'	'	$307,000,000
Net revenues	438,546,000	411,877,000	'
Income from continuing operations before taxes	43,803,000	35,368,000	'
Mayo Healthcare Pty Limited	'	'	'
Business Acquisition [Line Items]	'	'	'
Fair value of the consideration at the date of acquisition	28,519,000	'	'
Initial payment	29,000,000	'	'
Working capital adjustment related to acquisition	500,000	'	'
Transaction expenses	300,000	'	'
Net revenues	4,100,000	'	'
Income from continuing operations before taxes	$600,000	'	'
Mayo Healthcare Pty Limited | Customer Lists	'	'	'
Business Acquisition [Line Items]	'	'	'
Useful life of intangible assets acquired, years	'10 years	'	'

Fair_Values_Determination_of_A

Fair Values Determination of Assets Acquired and Liabilities Assumed in Acquisition (Detail) (USD $)	Mar. 30, 2014	Dec. 31, 2013	Mar. 30, 2013
In Thousands, unless otherwise specified			Mayo Healthcare Pty Limited
Business Acquisition [Line Items]	'	'	'
Current assets	'	'	$24,287
Property, plant and equipment	'	'	306
Customer lists intangible asset	'	'	9,335
Goodwill	1,372,058	1,354,203	15,986
Total assets acquired	'	'	49,914
Current liabilities	'	'	18,595
Deferred tax liabilities	'	'	2,800
Liabilities assumed	'	'	21,395
Net assets acquired	'	'	$28,519

Restructuring_and_Other_Impair2

Restructuring and Other Impairment Charges - Additional Information (Detail) (USD $)	3 Months Ended			1 Months Ended	3 Months Ended		12 Months Ended	15 Months Ended
	Mar. 30, 2014	Mar. 31, 2013	Mar. 30, 2014	Feb. 28, 2014	Mar. 30, 2014	Mar. 31, 2013	Dec. 31, 2013	Mar. 30, 2014	Mar. 30, 2014
	Segment		2014 European Restructuring Plan	2014 European Restructuring Plan	2013 Restructuring Program	2013 Restructuring Program	2013 Restructuring Program	2013 Restructuring Program	Two Thousand Twelve Restructuring Charges
				Employee Termination Benefit
Restructuring Cost And Reserve [Line Items]	'	'	'	'	'	'	'	'	'
Expected restructuring charges	'	'	'	$9,000,000	'	'	$11,000,000	'	'
Restructuring charges	7,780,000	4,665,000	8,318,000	'	168,000	480,000	'	10,400,000	'
Restructuring reserve	'	'	6,600,000	'	1,800,000	'	'	1,800,000	700,000
In-process research and development impairment	'	$4,494,000	'	'	'	'	'	'	'
Number of reportable segments	6	'	'	'	'	'	'	'	'

Reconciliation_of_Changes_in_A

Reconciliation of Changes in Accrued Liabilities Associated with Restructuring Program (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 30, 2014	Mar. 31, 2013
Restructuring Cost And Reserve [Line Items]	'	'
Subsequent accruals	$7,780	$4,665
Termination Benefits	'	'
Restructuring Cost And Reserve [Line Items]	'	'
Subsequent accruals	7,876	3,895
Facility Closure Costs	'	'
Restructuring Cost And Reserve [Line Items]	'	'
Subsequent accruals	376	161
Contract Termination Costs	'	'
Restructuring Cost And Reserve [Line Items]	'	'
Subsequent accruals	-472	442
LMA Restructuring Program	'	'
Restructuring Cost And Reserve [Line Items]	'	'
Balance, beginning	4,681	'
Subsequent accruals	-430	2,655
Cash payments	-501	'
Foreign currency translation	-4	'
Balance, ending	3,746	'
LMA Restructuring Program | Termination Benefits	'	'
Restructuring Cost And Reserve [Line Items]	'	'
Balance, beginning	552	'
Subsequent accruals	'	2,024
Cash payments	-276	'
Foreign currency translation	-1	'
Balance, ending	275	'
LMA Restructuring Program | Facility Closure Costs	'	'
Restructuring Cost And Reserve [Line Items]	'	'
Balance, beginning	427	'
Subsequent accruals	42	81
Cash payments	-81	'
Foreign currency translation	'	'
Balance, ending	388	'
LMA Restructuring Program | Contract Termination Costs	'	'
Restructuring Cost And Reserve [Line Items]	'	'
Balance, beginning	3,686	'
Subsequent accruals	-472	442
Cash payments	-144	'
Foreign currency translation	-3	'
Balance, ending	3,067	'
LMA Restructuring Program | Other Restructuring Costs	'	'
Restructuring Cost And Reserve [Line Items]	'	'
Balance, beginning	16	'
Subsequent accruals	'	'
Cash payments	'	'
Foreign currency translation	'	'
Balance, ending	$16	'

Restructuring_and_Other_Impair3

Restructuring and Other Impairment Charges (Detail) (USD $)	3 Months Ended		15 Months Ended
In Thousands, unless otherwise specified	Mar. 30, 2014	Mar. 31, 2013	Mar. 30, 2014
Restructuring Cost And Reserve [Line Items]	'	'	'
Restructuring charges	$7,780	$4,665	'
Impairment charges	'	4,494	'
Restructuring and other impairment charges	7,780	9,159	'
Termination Benefits	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'
Restructuring charges	7,876	3,895	'
Restructuring and other impairment charges	'	3,895	'
Facility Closure Costs	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'
Restructuring charges	376	161	'
Restructuring and other impairment charges	'	161	'
Contract Termination Costs	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'
Restructuring charges	-472	442	'
Restructuring and other impairment charges	'	442	'
Other	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'
Restructuring charges	'	167	'
Impairment charges	'	4,494	'
Restructuring and other impairment charges	'	4,661	'
LMA Restructuring Program	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'
Restructuring charges	-430	2,655	'
LMA Restructuring Program | Termination Benefits	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'
Restructuring charges	'	2,024	'
LMA Restructuring Program | Facility Closure Costs	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'
Restructuring charges	42	81	'
LMA Restructuring Program | Contract Termination Costs	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'
Restructuring charges	-472	442	'
LMA Restructuring Program | Other	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'
Restructuring charges	'	108	'
2014 European Restructuring Plan	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'
Restructuring charges	8,318	'	'
2014 European Restructuring Plan | Termination Benefits	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'
Restructuring charges	8,318	'	'
2013 Restructuring Program	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'
Restructuring charges	168	480	10,400
2013 Restructuring Program | Termination Benefits	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'
Restructuring charges	168	421	'
2013 Restructuring Program | Other	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'
Restructuring charges	'	59	'
2012 Restructuring Program	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'
Restructuring charges	-290	1,450	'
2012 Restructuring Program | Termination Benefits	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'
Restructuring charges	-610	1,450	'
2012 Restructuring Program | Facility Closure Costs	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'
Restructuring charges	320	'	'
2011 Restructuring Program	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'
Restructuring charges	14	'	'
2011 Restructuring Program | Facility Closure Costs	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'
Restructuring charges	14	'	'
2007 Arrow Integration Program	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'
Restructuring charges	'	80	'
2007 Arrow Integration Program | Facility Closure Costs	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'
Restructuring charges	'	$80	'

Restructuring_and_Other_Impair4

Restructuring and Other Impairment Charges by Segment (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 30, 2014	Mar. 31, 2013
Restructuring and other impairment charges	'	'
Total restructuring and other impairment charges	$7,780	$9,159
Vascular North America	'	'
Restructuring and other impairment charges	'	'
Total restructuring and other impairment charges	14	497
Anesthesia Respiratory North America	'	'
Restructuring and other impairment charges	'	'
Total restructuring and other impairment charges	27	1,906
Surgical North America	'	'
Restructuring and other impairment charges	'	'
Total restructuring and other impairment charges	0	4,494
EMEA	'	'
Restructuring and other impairment charges	'	'
Total restructuring and other impairment charges	7,889	1,294
Asia	'	'
Restructuring and other impairment charges	'	'
Total restructuring and other impairment charges	78	98
All Other	'	'
Restructuring and other impairment charges	'	'
Total restructuring and other impairment charges	($228)	$870

Inventories_Net_Detail

Inventories, Net (Detail) (USD $)	Mar. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory [Line Items]	'	'
Raw materials	$72,047	$70,209
Work-in-process	57,632	53,672
Finished goods	253,760	242,113
Inventories, gross	383,439	365,994
Less: Inventory reserve	-33,694	-32,373
Inventories, net	$349,745	$333,621

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets, Net - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 30, 2014	Mar. 31, 2013
	Segment
Finite Lived Intangible Assets [Line Items]	'	'
Number of reportable segments	6	'
In-process research and development impairment	'	$4,494,000
Amortization expense of intangible assets	16,019,000	12,438,000
Semprus Technology	'	'
Finite Lived Intangible Assets [Line Items]	'	'
Net Assets	$38,000,000	'

Changes_in_Carrying_Amount_of_

Changes in Carrying Amount of Goodwill, by Reporting Segment (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 30, 2014	Dec. 31, 2013
Goodwill [Line Items]	'	'
Goodwill gross	$1,704,186	$1,686,331
Accumulated impairment losses	-332,128	-332,128
Goodwill net	1,354,203	'
Goodwill related to acquisitions	15,986	'
Translation adjustment	1,869	'
Goodwill net	1,372,058	'
Vascular North America	'	'
Goodwill [Line Items]	'	'
Goodwill gross	474,044	474,044
Accumulated impairment losses	-219,527	-219,527
Goodwill net	254,517	'
Goodwill related to acquisitions	0	'
Translation adjustment	0	'
Goodwill net	254,517	'
Anesthesia Respiratory North America	'	'
Goodwill [Line Items]	'	'
Goodwill gross	166,793	167,195
Accumulated impairment losses	-107,073	-107,073
Goodwill net	60,122	'
Goodwill related to acquisitions	0	'
Translation adjustment	-402	'
Goodwill net	59,720	'
Surgical North America	'	'
Goodwill [Line Items]	'	'
Goodwill gross	250,506	250,506
Accumulated impairment losses	0	0
Goodwill net	250,506	'
Goodwill related to acquisitions	0	'
Translation adjustment	0	'
Goodwill net	250,506	'
EMEA	'	'
Goodwill [Line Items]	'	'
Goodwill gross	375,032	373,417
Accumulated impairment losses	0	0
Goodwill net	373,417	'
Goodwill related to acquisitions	0	'
Translation adjustment	1,615	'
Goodwill net	375,032	'
Asia	'	'
Goodwill [Line Items]	'	'
Goodwill gross	154,031	136,946
Accumulated impairment losses	0	0
Goodwill net	136,946	'
Goodwill related to acquisitions	15,986	'
Translation adjustment	1,099	'
Goodwill net	154,031	'
All Other	'	'
Goodwill [Line Items]	'	'
Goodwill gross	283,780	284,223
Accumulated impairment losses	-5,528	-5,528
Goodwill net	278,695	'
Goodwill related to acquisitions	0	'
Translation adjustment	-443	'
Goodwill net	$278,252	'

Components_of_Intangible_Asset

Components of Intangible Assets (Detail) (USD $)	Mar. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Finite Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	$1,569,026	$1,557,688
Accumulated Amortization	-318,493	-302,091
In Process Research and Development	'	'
Finite Lived Intangible Assets [Line Items]	'	'
In-process research and development	68,786	68,786
Customer relationships	'	'
Finite Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	638,476	628,020
Accumulated Amortization	-176,053	-168,223
Intellectual property	'	'
Finite Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	436,189	435,869
Accumulated Amortization	-125,872	-118,086
Distribution rights	'	'
Finite Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	16,863	16,797
Accumulated Amortization	-14,743	-14,592
Trade names	'	'
Finite Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	408,375	407,879
Accumulated Amortization	-1,713	-1,148
Noncompete agreements	'	'
Finite Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	337	337
Accumulated Amortization	($112)	($42)

Estimated_Annual_Amortization_

Estimated Annual Amortization Expense (Detail) (USD $)	Mar. 30, 2014
In Thousands, unless otherwise specified
Finite Lived Intangible Assets [Line Items]	'
2014	$49,100
2015	55,500
2016	54,500
2017	54,000
2018	53,500
2019	$51,000

Components_of_LongTerm_Debt_De

Components of Long-Term Debt (Detail) (USD $)	Mar. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'	'
Revolving credit facility, at a rate of 2.15% at March 30, 2014, due 7/16/2018	$680,000	$680,000
Long-term debt, Gross	1,330,000	1,330,000
Less: Unamortized debt discount on 3.875% Convertible Senior Subordinated Notes	-45,439	-48,413
Total long-term debt	1,284,561	1,281,587
Current portion of borrowings	-354,561	-351,587
Long-term borrowings	930,000	930,000
3.875% Convertible Senior Subordinated Notes	'	'
Debt Instrument [Line Items]	'	'
3.875% Convertible Senior Subordinated Notes	400,000	400,000
6.875% Senior Subordinated Notes due 2019	'	'
Debt Instrument [Line Items]	'	'
6.875% Senior Subordinated Notes due 2019	$250,000	$250,000

Components_of_LongTerm_Debt_Pa

Components of Long-Term Debt (Parenthetical) (Detail)	3 Months Ended
	Mar. 30, 2014	Mar. 30, 2014	Dec. 31, 2013	Mar. 30, 2014	Dec. 31, 2013
		3.875% Convertible Senior Subordinated Notes	3.875% Convertible Senior Subordinated Notes	6.875% Senior Subordinated Notes due 2019	6.875% Senior Subordinated Notes due 2019
Debt Instrument [Line Items]	'	'	'	'	'
Revolving credit facility interest rate	2.15%	'	'	'	'
Convertible senior notes percentage	3.88%	3.88%	3.88%	6.88%	6.88%
Debt instrument maturity date	'	'	'	'2019	'2019
Revolving credit facility maturity date	16-Jul-18	'	'	'	'

Borrowings_Additional_Informat

Borrowings - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 30, 2014	Dec. 31, 2013
Debt Instrument [Line Items]	'	'
Convertible senior notes percentage	3.88%	'
Convertible notes, threshold number of trading days to trigger conversion feature	'20 days	'
Convertible notes, threshold percentage of stock price trigger	130.00%	130.00%
Convertible notes, stock price trigger	$79.72	'
Total Long-term Debt	$1,284,561	$1,281,587
3.875% Convertible Senior Subordinated Notes	'	'
Debt Instrument [Line Items]	'	'
Convertible senior notes percentage	3.88%	'
Debt instrument maturity date	'2017	'

Fair_Values_of_Derivative_Inst

Fair Values of Derivative Instruments Designated as Hedging Instruments (Detail) (USD $)	Mar. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Derivatives Fair Value [Line Items]	'	'
Total asset derivatives	$684	'
Total liability derivatives	493	'
Prepaid Expenses and Other Current Assets | Foreign Exchange Contracts	'	'
Derivatives Fair Value [Line Items]	'	'
Total asset derivatives	684	'
Other Current Liabilities | Foreign Exchange Contracts	'	'
Derivatives Fair Value [Line Items]	'	'
Total liability derivatives	$493	'

Financial_Instruments_Addition

Financial Instruments - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 30, 2014	Mar. 31, 2013
Derivatives Fair Value [Line Items]	'	'
Total notional amount for all open contracts	$68,800,000	'
Amount of loss in accumulated other comprehensive income to be reclassified as expense to the statement of income	100,000	'
Net revenues	438,546,000	411,877,000
Spain, Italy, Portugal, and Greece	'	'
Derivatives Fair Value [Line Items]	'	'
Net revenues	$39,300,000	$37,200,000

After_Tax_GainLoss_Reclassifie

After Tax (Gain)/Loss Reclassified from Accumulated Other Comprehensive Income into Income (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 30, 2014	Mar. 31, 2013
Derivative Instruments Gain Loss [Line Items]	'	'
Derivatives qualifying as hedges, net of tax	$70	$180
Foreign Exchange Contracts	'	'
Derivative Instruments Gain Loss [Line Items]	'	'
Derivatives qualifying as hedges, net of tax	$70	$180

Aggregate_Accounts_Receivable_

Aggregate Accounts Receivable, Net of Allowance for Doubtful Accounts (Detail) (Spain, Italy, Portugal, and Greece, USD $)	3 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Mar. 30, 2014		Dec. 31, 2013
Spain, Italy, Portugal, and Greece	'		'
Accounts Notes And Loans Receivable [Line Items]	'		'
Current and long-term accounts receivable, net	$97,885	[1]	$97,852	[1]
Percentage of total net current and long-term accounts receivable	32.00%		31.00%
[1]	The long-term portion of accounts receivable at March 30, 2014 and December 31, 2013 were $15.0 million and $17.6 million, respectively.

Aggregate_Accounts_Receivable_1

Aggregate Accounts Receivable, Net of Allowance for Doubtful Accounts (Parenthetical) (Detail) (Spain, Italy, Portugal, and Greece, USD $)	Mar. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Spain, Italy, Portugal, and Greece	'	'
Accounts Notes And Loans Receivable [Line Items]	'	'
Current and long-term accounts receivable, allowances	$8.20	$7.90
Long-term portion of accounts receivable	$15	$17.60

Financial_Assets_and_Liabiliti

Financial Assets and Liabilities Carried at Fair Value Measured on Recurring Basis (Detail) (USD $)	Mar. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]	'	'
Investments in marketable securities	$6,259	$6,150
Derivative assets	684	'
Derivative liabilities	493	'
Contingent consideration liabilities	17,942	20,313
Quoted Prices In Active Markets (Level 1)	'	'
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]	'	'
Investments in marketable securities	6,259	6,150
Derivative assets	'	'
Derivative liabilities	'	'
Contingent consideration liabilities	'	'
Significant Other Observable Inputs (Level 2)	'	'
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]	'	'
Investments in marketable securities	'	'
Derivative assets	684	'
Derivative liabilities	493	'
Contingent consideration liabilities	'	'
Significant Unobservable Inputs (Level 3)	'	'
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]	'	'
Investments in marketable securities	'	'
Derivative assets	'	'
Derivative liabilities	'	'
Contingent consideration liabilities	$17,942	$20,313

Reconciliation_of_Changes_in_L

Reconciliation of Changes in Level Three Financial Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 30, 2014
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]	'
Beginning balance	$20,313
Revaluations	-2,371
Ending balance	$17,942

Fair_Value_Measurement_Additio

Fair Value Measurement - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 30, 2014
Fair Value Measurements [Line Items]	'
Reversal of contingent consideration	$2.30
Contingent consideration	17.9
Current contingent consideration	1.7
Other liabilities	16.2
Minimum	'
Fair Value Measurements [Line Items]	'
Fair value of contingent consideration liability associated with future milestone	0
Maximum	'
Fair Value Measurements [Line Items]	'
Fair value of contingent consideration liability associated with future milestone	$61

Fair_Value_of_LongTerm_Debt_De

Fair Value of Long-Term Debt (Detail) (USD $)	Mar. 30, 2014
In Thousands, unless otherwise specified
Fair Value Measurements [Line Items]	'
Fair value of long-term debt	$1,622,804
Level 1	'
Fair Value Measurements [Line Items]	'
Fair value of long-term debt	969,595
Level 2	'
Fair Value Measurements [Line Items]	'
Fair value of long-term debt	$653,209

Valuation_Technique_and_Inputs

Valuation Technique and Inputs Used to Determine Fair Value of Assets or Liabilities (Detail)	3 Months Ended
	Mar. 30, 2014
Discount Rate	'
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]	'
Contingent consideration, weighted average	6.00%
Probability of Payment	'
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]	'
Contingent consideration, weighted average	35.00%
Minimum | Discount Rate	'
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]	'
Contingent consideration	1.00%
Minimum | Probability of Payment	'
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]	'
Contingent consideration	0.00%
Maximum | Discount Rate	'
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]	'
Contingent consideration	10.00%
Maximum | Probability of Payment	'
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]	'
Contingent consideration	100.00%

Changes_in_Shareholders_Equity2

Changes in Shareholder's Equity - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Jun. 30, 2007	Mar. 30, 2014	Mar. 31, 2013
Shareholders Equity [Line Items]	'	'	'
Repurchase of outstanding common stock, authorized amount	$300	'	'
Per share market price of common stock	'	$61.32	'
Strike price of warrants	'	$74.65	$74.65
Conversion of convertible notes, shares issued upon conversion	'	1.6	0.3
Stock Option	'	'	'
Shareholders Equity [Line Items]	'	'	'
Weighted average antidilutive which were not included in the calculation of earnings per share	'	6.5	7.8
Convertible Note	'	'	'
Shareholders Equity [Line Items]	'	'	'
Weighted average antidilutive which were not included in the calculation of earnings per share	'	2.5	1.4

Reconciliation_of_Basic_to_Dil

Reconciliation of Basic to Diluted Weighted Average Common Shares Outstanding (Detail)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 30, 2014	Mar. 31, 2013
Schedule Of Earnings Per Share Basic And Diluted By Common Class [Line Items]	'	'
Basic	41,262	41,014
Dilutive effect of share based awards	471	393
Dilutive effect of 3.875% Convertible Notes and warrants	4,016	1,640
Diluted	45,749	43,047

Reconciliation_of_Basic_to_Dil1

Reconciliation of Basic to Diluted Weighted Average Common Shares Outstanding (Parenthetical) (Detail)	Mar. 30, 2014
Schedule Of Earnings Per Share Basic And Diluted By Common Class [Line Items]	'
Convertible senior notes percentage	3.88%

Change_in_Accumulated_Other_Co

Change in Accumulated Other Comprehensive Income (Loss), Net of tax (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 30, 2014	Mar. 31, 2013
Accumulated Other Comprehensive Income Loss [Line Items]	'	'
Beginning balance, accumulated other comprehensive income (loss), net of tax	($110,855)	($132,048)
Other comprehensive income (loss) before reclassifications	4,005	-26,656
Amounts reclassified from accumulated other comprehensive income (loss)	740	1,180
Net current-period other comprehensive income	4,745	-25,476
Ending balance, accumulated other comprehensive income (loss), net of tax	-106,110	-157,524
Cash Flow Hedges	'	'
Accumulated Other Comprehensive Income Loss [Line Items]	'	'
Beginning balance, accumulated other comprehensive income (loss), net of tax	'	-381
Other comprehensive income (loss) before reclassifications	113	455
Amounts reclassified from accumulated other comprehensive income (loss)	-43	-275
Net current-period other comprehensive income	70	180
Ending balance, accumulated other comprehensive income (loss), net of tax	70	-201
Pension and Other Postretirement Benefits Plans	'	'
Accumulated Other Comprehensive Income Loss [Line Items]	'	'
Beginning balance, accumulated other comprehensive income (loss), net of tax	-97,037	-127,257
Other comprehensive income (loss) before reclassifications	-159	-365
Amounts reclassified from accumulated other comprehensive income (loss)	783	1,455
Net current-period other comprehensive income	624	1,090
Ending balance, accumulated other comprehensive income (loss), net of tax	-96,413	-126,167
Foreign Currency Translation Adjustment	'	'
Accumulated Other Comprehensive Income Loss [Line Items]	'	'
Beginning balance, accumulated other comprehensive income (loss), net of tax	-13,818	-4,410
Other comprehensive income (loss) before reclassifications	4,051	-26,746
Amounts reclassified from accumulated other comprehensive income (loss)	0	'
Net current-period other comprehensive income	4,051	-26,746
Ending balance, accumulated other comprehensive income (loss), net of tax	($9,767)	($31,156)

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income (Loss) into Income Expense (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 30, 2014		Mar. 31, 2013
Accumulated Other Comprehensive Income Loss [Line Items]	'		'
Cost of goods sold	($217,387)		($211,357)
Income from continuing operations before taxes	43,803		35,368
Tax expense	-8,534		-7,667
Net of tax	35,269		27,701
Reclassification out of Accumulated Other Comprehensive Income	'		'
Accumulated Other Comprehensive Income Loss [Line Items]	'		'
Total reclassifications, net of tax	740		1,180
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges | Reclassification out of Accumulated Other Comprehensive Income	'		'
Accumulated Other Comprehensive Income Loss [Line Items]	'		'
Income from continuing operations before taxes	-77		-502
Tax expense	34		227
Net of tax	-43		-275
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges | Commodity Contract | Reclassification out of Accumulated Other Comprehensive Income	'		'
Accumulated Other Comprehensive Income Loss [Line Items]	'		'
Cost of goods sold	-77		-502
Pension and Other Postretirement Benefits Plans | Reclassification out of Accumulated Other Comprehensive Income	'		'
Accumulated Other Comprehensive Income Loss [Line Items]	'		'
Income from continuing operations before taxes	1,097		2,140
Tax expense	-314		-685
Net of tax	783		1,455
Actuarial losses/(gains)	1,102	[1]	2,145	[1]
Prior-service costs	-5	[1]	-6	[1]
Transition obligation	$0	[1]	$1	[1]
[1]	These accumulated other comprehensive income components are included in the computation of net benefit cost of pension and other postretirement benefit plans (see Note 12 for additional information).

Effective_Income_Tax_Rate_Deta

Effective Income Tax Rate (Detail)	3 Months Ended
	Mar. 30, 2014	Mar. 31, 2013
Income Taxes [Line Items]	'	'
Effective income tax rate	19.50%	21.70%

Taxes_on_Income_from_Continuin2

Taxes on Income from Continuing Operations - Additional Information (Detail)	3 Months Ended
	Mar. 30, 2014	Mar. 31, 2013
Income Taxes [Line Items]	'	'
Effective income tax rate	19.50%	21.70%

Net_Benefit_Cost_of_Pension_an

Net Benefit Cost of Pension and Postretirement Benefit Plans (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 30, 2014	Mar. 31, 2013
Pension	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'
Service cost	$450	$465
Interest cost	4,483	4,139
Expected return on plan assets	-6,260	-5,770
Net amortization and deferral	1,071	1,410
Net benefit cost	-256	244
Postretirement Benefits	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'
Service cost	138	164
Interest cost	597	999
Expected return on plan assets	0	'
Net amortization and deferral	26	730
Net benefit cost	$761	$1,893

Pension_and_Other_Postretireme2

Pension and Other Postretirement Benefits - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 30, 2014
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]	'
Expected employer contribution for year 2014	$9.40
Employer contribution to pension plan	$2.40

Recovered_Sheet1

Commitments and Contingent Liabilities - Additional Information (Detail) (USD $)	Mar. 30, 2014	Dec. 31, 2013	Mar. 30, 2014	Mar. 30, 2014	Mar. 30, 2014	Mar. 30, 2014	Mar. 30, 2014	Mar. 30, 2014
In Millions, unless otherwise specified			Minimum	Maximum	Accrued Liabilities	Other Liability	Property, Plant and Equipment	Property, Plant and Equipment
								Build To Suit Lease
Loss Contingencies [Line Items]	'	'	'	'	'	'	'	'
Estimated fair value of the costs to construct buildings	'	'	'	'	'	'	$14.80	$28.30
Expected construction completion year	'	'	'	'	'	'	'	'2014-11
Lease commencement date	'	'	'	'	'	'	'	1-Sep-13
Waste disposed accrued liability	'	'	'	'	2	5.5	'	'
Time-frame over which the accrued amounts may be paid out, in years	'	'	'15 years	'20 years	'	'	'	'
Contingency reserve for litigation	$3.90	$6.80	'	'	'	'	'	'

Segment_Result_Detail

Segment Result (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 30, 2014		Mar. 31, 2013
	Segment
Revenues From External Customers And Long Lived Assets [Line Items]	'		'
Revenue	$438,546		$411,877
Income from continuing operations before Interest and taxes	59,020		49,404
Number of reportable segments	6		'
All Other	'		'
Revenues From External Customers And Long Lived Assets [Line Items]	'		'
Revenue	38,539		49,775
Operating Segments	'		'
Revenues From External Customers And Long Lived Assets [Line Items]	'		'
Revenue	438,546		411,877
Operating Profit	81,717	[1]	68,079	[1]
Unallocated expenses	-22,697	[2]	-18,675	[2]
Income from continuing operations before Interest and taxes	59,020		49,404
Depreciation and Amortization	31,413		26,341
Operating Segments | Vascular North America	'		'
Revenues From External Customers And Long Lived Assets [Line Items]	'		'
Revenue	62,506		56,674
Operating Profit	9,392		5,026
Depreciation and Amortization	7,855		6,559
Operating Segments | Anesthesia Respiratory North America	'		'
Revenues From External Customers And Long Lived Assets [Line Items]	'		'
Revenue	54,714		58,174
Operating Profit	5,687		5,678
Depreciation and Amortization	4,428		3,841
Operating Segments | Surgical North America	'		'
Revenues From External Customers And Long Lived Assets [Line Items]	'		'
Revenue	35,231		36,688
Operating Profit	10,548		13,662
Depreciation and Amortization	2,369		2,554
Operating Segments | EMEA	'		'
Revenues From External Customers And Long Lived Assets [Line Items]	'		'
Revenue	150,245		142,418
Operating Profit	26,881		23,242
Depreciation and Amortization	8,937		7,151
Operating Segments | Asia	'		'
Revenues From External Customers And Long Lived Assets [Line Items]	'		'
Revenue	49,602		42,368
Operating Profit	12,837		12,096
Depreciation and Amortization	1,838		1,212
Operating Segments | OEM	'		'
Revenues From External Customers And Long Lived Assets [Line Items]	'		'
Revenue	33,182		31,338
Operating Profit	6,604		6,360
Depreciation and Amortization	1,456		1,148
Operating Segments | All Other	'		'
Revenues From External Customers And Long Lived Assets [Line Items]	'		'
Revenue	53,066		44,217
Operating Profit	9,768		2,015
Depreciation and Amortization	$4,530		$3,876
[1]	Segment operating profit includes segment net revenues from external customers reduced by its standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses.
[2]	Unallocated expenses primarily include manufacturing variances with the exception of fixed manufacturing cost absorption variances and restructuring and other impairment charges.

Total_Net_Revenues_and_Total_N

Total Net Revenues and Total Net Property, Plant and Equipment by Geographic Region (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 30, 2014	Mar. 31, 2013	Dec. 31, 2013
Segment Reporting Information [Line Items]	'	'	'
Net revenues	$438,546	$411,877	'
Property, plant and equipment, net	328,679	'	325,900
United States	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net revenues	216,461	207,514	'
Property, plant and equipment, net	203,005	'	203,985
Other Americas	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net revenues	14,771	14,151	'
Property, plant and equipment, net	11,933	'	12,350
Germany	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net revenues	33,991	33,751	'
Property, plant and equipment, net	12,191	'	12,135
Other Europe	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net revenues	134,784	106,686	'
Property, plant and equipment, net	63,991	'	61,891
All Other	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net revenues	38,539	49,775	'
Property, plant and equipment, net	$37,559	'	$35,539

Condensed_Consolidating_Guaran

Condensed Consolidating Guarantor Financial Information - Additional Information (Detail) (USD $)	Mar. 30, 2014	Jun. 26, 2011
In Thousands, unless otherwise specified		6.875% Senior Subordinated Notes due 2019
Condensed Financial Statements Captions [Line Items]	'	'
Senior subordinated notes	'	$250,000
Interest rate	3.88%	6.88%
Ownership percentage of subsidiaries	100.00%	'

Adjustments_to_Condensed_Conso

Adjustments to Condensed Consolidating Statements of Cash Flows within Guarantor Financial Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 30, 2014	Mar. 31, 2013
Cash Flows from Operating Activities of Continuing Operations	$33,600	$5,264
Intercompany transactions	0	'
Intercompany dividends paid	'	'
Cash Flows from Financing Activities of Continuing Operations	-5,500	-15,988
Consolidation, Eliminations	'	'
Cash Flows from Operating Activities of Continuing Operations	0	-47,541
Intercompany transactions	0	'
Intercompany dividends paid	'	47,541
Cash Flows from Financing Activities of Continuing Operations	0	47,541
Scenario, Adjustment	'	'
Intercompany transactions	'	'
Intercompany dividends paid	'	'
Scenario, Adjustment | Before Adjustment	'	'
Cash Flows from Operating Activities of Continuing Operations	'	'
Scenario, Adjustment | After Adjustment	'	'
Cash Flows from Financing Activities of Continuing Operations	'	'
Scenario, Adjustment | Consolidation, Eliminations	'	'
Intercompany dividends paid	'	47,541
Scenario, Adjustment | Consolidation, Eliminations | Before Adjustment	'	'
Cash Flows from Operating Activities of Continuing Operations	'	-47,541
Scenario, Adjustment | Consolidation, Eliminations | After Adjustment	'	'
Cash Flows from Financing Activities of Continuing Operations	'	47,541
Parent Company	'	'
Cash Flows from Operating Activities of Continuing Operations	-30,503	-37,035
Intercompany transactions	15,776	22,271
Intercompany dividends paid	'	'
Cash Flows from Financing Activities of Continuing Operations	10,276	13,462
Parent Company | Scenario, Adjustment	'	'
Intercompany transactions	'	-1,200
Parent Company | Scenario, Adjustment | Before Adjustment	'	'
Cash Flows from Operating Activities of Continuing Operations	'	1,200
Parent Company | Scenario, Adjustment | After Adjustment	'	'
Cash Flows from Financing Activities of Continuing Operations	'	-1,200
Guarantor Subsidiaries	'	'
Cash Flows from Operating Activities of Continuing Operations	24,438	64,415
Intercompany transactions	-28,602	-32,594
Intercompany dividends paid	'	-17,400
Cash Flows from Financing Activities of Continuing Operations	-28,602	-55,775
Guarantor Subsidiaries | Scenario, Adjustment	'	'
Intercompany transactions	'	-26,944
Intercompany dividends paid	'	-17,400
Guarantor Subsidiaries | Scenario, Adjustment | Before Adjustment	'	'
Cash Flows from Operating Activities of Continuing Operations	'	44,344
Guarantor Subsidiaries | Scenario, Adjustment | After Adjustment	'	'
Cash Flows from Financing Activities of Continuing Operations	'	-44,344
Non-Guarantor Subsidiaries	'	'
Cash Flows from Operating Activities of Continuing Operations	39,665	25,425
Intercompany transactions	12,826	10,323
Intercompany dividends paid	'	-30,141
Cash Flows from Financing Activities of Continuing Operations	12,826	-21,216
Non-Guarantor Subsidiaries | Scenario, Adjustment	'	'
Intercompany transactions	'	28,144
Intercompany dividends paid	'	-30,141
Non-Guarantor Subsidiaries | Scenario, Adjustment | Before Adjustment	'	'
Cash Flows from Operating Activities of Continuing Operations	'	1,997
Non-Guarantor Subsidiaries | Scenario, Adjustment | After Adjustment	'	'
Cash Flows from Financing Activities of Continuing Operations	'	($1,997)

Condensed_Consolidating_Statem

Condensed Consolidating Statements of Income and Comprehensive Income (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 30, 2014	Mar. 31, 2013
Condensed Income Statements Captions [Line Items]	'	'
Net revenues	$438,546	$411,877
Cost of goods sold	217,387	211,357
Gross profit	221,159	200,520
Selling, general and administrative expenses	140,297	126,950
Research and development expenses	14,062	15,007
Restructuring and other impairment charges	7,780	9,159
Income (loss) from continuing operations before interest and taxes	59,020	49,404
Interest expense	15,404	14,193
Interest income	-187	-157
Income from continuing operations before taxes	43,803	35,368
Taxes (benefit) on income (loss) from continuing operations	8,534	7,667
Equity in net income of consolidated subsidiaries	0	'
Income from continuing operations	35,269	27,701
Operating loss from discontinued operations	-25	-758
Taxes (benefit) on loss from discontinued operations	100	-296
Income (loss) from discontinued operations	-125	-462
Net income	35,144	27,239
Less: Income from continuing operations attributable to noncontrolling interests	186	201
Net income attributable to common shareholders	34,958	27,038
Other comprehensive income (loss) attributable to common shareholders	4,745	-25,476
Comprehensive income attributable to common shareholders	39,703	1,562
Consolidation, Eliminations	'	'
Condensed Income Statements Captions [Line Items]	'	'
Net revenues	-72,316	-73,784
Cost of goods sold	-72,854	-72,920
Gross profit	538	-864
Selling, general and administrative expenses	203	194
Research and development expenses	0	'
Restructuring and other impairment charges	0	'
Income (loss) from continuing operations before interest and taxes	335	-1,058
Interest expense	0	'
Interest income	0	'
Income from continuing operations before taxes	335	-1,058
Taxes (benefit) on income (loss) from continuing operations	-2,096	651
Equity in net income of consolidated subsidiaries	-107,326	-93,970
Income from continuing operations	-104,895	-95,679
Operating loss from discontinued operations	0	'
Taxes (benefit) on loss from discontinued operations	0	'
Income (loss) from discontinued operations	0	'
Net income	-104,895	-95,679
Less: Income from continuing operations attributable to noncontrolling interests	0	'
Net income attributable to common shareholders	-104,895	-95,679
Other comprehensive income (loss) attributable to common shareholders	-15,751	55,939
Comprehensive income attributable to common shareholders	-120,646	-39,740
Parent Company	'	'
Condensed Income Statements Captions [Line Items]	'	'
Net revenues	0	'
Cost of goods sold	0	'
Gross profit	0	'
Selling, general and administrative expenses	10,778	16,928
Research and development expenses	0	'
Restructuring and other impairment charges	0	'
Income (loss) from continuing operations before interest and taxes	-10,778	-16,928
Interest expense	33,726	33,535
Interest income	0	-6
Income from continuing operations before taxes	-44,504	-50,457
Taxes (benefit) on income (loss) from continuing operations	-15,420	-18,459
Equity in net income of consolidated subsidiaries	64,124	59,820
Income from continuing operations	35,040	27,822
Operating loss from discontinued operations	-25	-1,126
Taxes (benefit) on loss from discontinued operations	57	-342
Income (loss) from discontinued operations	-82	-784
Net income	34,958	27,038
Less: Income from continuing operations attributable to noncontrolling interests	0	'
Net income attributable to common shareholders	34,958	27,038
Other comprehensive income (loss) attributable to common shareholders	4,745	-25,476
Comprehensive income attributable to common shareholders	39,703	1,562
Guarantor Subsidiaries	'	'
Condensed Income Statements Captions [Line Items]	'	'
Net revenues	262,425	254,856
Cost of goods sold	152,368	152,704
Gross profit	110,057	102,152
Selling, general and administrative expenses	81,395	67,156
Research and development expenses	12,010	13,007
Restructuring and other impairment charges	-188	7,767
Income (loss) from continuing operations before interest and taxes	16,840	14,222
Interest expense	-19,907	-21,127
Interest income	0	'
Income from continuing operations before taxes	36,747	35,349
Taxes (benefit) on income (loss) from continuing operations	17,218	14,251
Equity in net income of consolidated subsidiaries	43,108	34,150
Income from continuing operations	62,637	55,248
Operating loss from discontinued operations	0	'
Taxes (benefit) on loss from discontinued operations	0	'
Income (loss) from discontinued operations	0	'
Net income	62,637	55,248
Less: Income from continuing operations attributable to noncontrolling interests	0	'
Net income attributable to common shareholders	62,637	55,248
Other comprehensive income (loss) attributable to common shareholders	7,228	-32,126
Comprehensive income attributable to common shareholders	69,865	23,122
Non-Guarantor Subsidiaries	'	'
Condensed Income Statements Captions [Line Items]	'	'
Net revenues	248,437	230,805
Cost of goods sold	137,873	131,573
Gross profit	110,564	99,232
Selling, general and administrative expenses	47,921	42,672
Research and development expenses	2,052	2,000
Restructuring and other impairment charges	7,968	1,392
Income (loss) from continuing operations before interest and taxes	52,623	53,168
Interest expense	1,585	1,785
Interest income	-187	-151
Income from continuing operations before taxes	51,225	51,534
Taxes (benefit) on income (loss) from continuing operations	8,832	11,224
Equity in net income of consolidated subsidiaries	94	'
Income from continuing operations	42,487	40,310
Operating loss from discontinued operations	0	368
Taxes (benefit) on loss from discontinued operations	43	46
Income (loss) from discontinued operations	-43	322
Net income	42,444	40,632
Less: Income from continuing operations attributable to noncontrolling interests	186	201
Net income attributable to common shareholders	42,258	40,431
Other comprehensive income (loss) attributable to common shareholders	8,523	-23,813
Comprehensive income attributable to common shareholders	$50,781	$16,618

Condensed_Consolidating_Balanc

Condensed Consolidating Balance Sheets (Detail) (USD $)	Mar. 30, 2014	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets	'	'	'	'
Cash and cash equivalents	$421,649	$431,984	$306,554	$337,039
Accounts receivable, net	295,514	295,290	'	'
Accounts receivable from consolidated subsidiaries	0	'	'	'
Inventories, net	349,745	333,621	'	'
Prepaid expenses and other current assets	47,543	39,810	'	'
Prepaid taxes	42,470	36,504	'	'
Deferred tax assets	51,983	52,917	'	'
Assets held for sale	11,714	10,428	'	'
Total current assets	1,220,618	1,200,554	'	'
Property, plant and equipment, net	328,679	325,900	'	'
Goodwill	1,372,058	1,354,203	'	'
Intangibles assets, net	1,250,533	1,255,597	'	'
Investments in affiliates	1,513	1,715	'	'
Deferred tax assets	944	943	'	'
Notes receivable and other amounts due from consolidated subsidiaries	0	'	'	'
Other assets	67,789	70,095	'	'
Total assets	4,242,134	4,209,007	'	'
Current liabilities	'	'	'	'
Current borrowings	359,261	356,287	'	'
Accounts payable	71,094	71,967	'	'
Accounts payable to consolidated subsidiaries	0	'	'	'
Accrued expenses	79,455	74,868	'	'
Current portion of contingent consideration	1,658	4,131	'	'
Payroll and benefit-related liabilities	60,185	73,090	'	'
Accrued interest	9,066	8,725	'	'
Income taxes payable	27,451	23,821	'	'
Other current liabilities	23,637	22,231	'	'
Total current liabilities	631,807	635,120	'	'
Long-term borrowings	930,000	930,000	'	'
Deferred tax liabilities	523,445	514,715	'	'
Pension and postretirement benefit liabilities	106,092	109,498	'	'
Noncurrent liability for uncertain tax provisions	55,956	55,152	'	'
Notes payable and other amounts due from consolidated subsidiaries	0	'	'	'
Other liabilities	49,607	48,506	'	'
Total liabilities	2,296,907	2,292,991	'	'
Total common shareholders' equity	1,942,486	1,913,527	'	'
Noncontrolling interest	2,741	2,489	'	'
Total equity	1,945,227	1,916,016	1,775,077	1,781,537
Total liabilities and equity	4,242,134	4,209,007	'	'
Consolidation, Eliminations	'	'	'	'
Current assets	'	'	'	'
Cash and cash equivalents	0	0	'	'
Accounts receivable, net	3,269	3,472	'	'
Accounts receivable from consolidated subsidiaries	-2,872,780	-2,880,648	'	'
Inventories, net	-15,171	-15,709	'	'
Prepaid expenses and other current assets	0	'	'	'
Prepaid taxes	0	'	'	'
Deferred tax assets	-4	-3	'	'
Assets held for sale	0	'	'	'
Total current assets	-2,884,686	-2,892,888	'	'
Property, plant and equipment, net	0	'	'	'
Goodwill	0	'	'	'
Intangibles assets, net	0	'	'	'
Investments in affiliates	-7,110,713	-6,987,772	'	'
Deferred tax assets	-36,822	-39,410	'	'
Notes receivable and other amounts due from consolidated subsidiaries	-3,932,914	-1,936,618	'	'
Other assets	0	'	'	'
Total assets	-13,965,135	-11,856,688	'	'
Current liabilities	'	'	'	'
Current borrowings	0	'	'	'
Accounts payable	0	'	'	'
Accounts payable to consolidated subsidiaries	-2,872,780	-2,880,648	'	'
Accrued expenses	0	'	'	'
Current portion of contingent consideration	0	'	'	'
Payroll and benefit-related liabilities	0	'	'	'
Accrued interest	0	'	'	'
Income taxes payable	0	'	'	'
Other current liabilities	-4	-4	'	'
Total current liabilities	-2,872,784	-2,880,652	'	'
Long-term borrowings	0	'	'	'
Deferred tax liabilities	-36,822	-39,409	'	'
Pension and postretirement benefit liabilities	0	'	'	'
Noncurrent liability for uncertain tax provisions	0	'	'	'
Notes payable and other amounts due from consolidated subsidiaries	-3,938,493	-1,940,100	'	'
Other liabilities	0	'	'	'
Total liabilities	-6,848,099	-4,860,161	'	'
Total common shareholders' equity	-7,117,036	-6,996,527	'	'
Noncontrolling interest	0	'	'	'
Total equity	-7,117,036	-6,996,527	'	'
Total liabilities and equity	-13,965,135	-11,856,688	'	'
Parent Company	'	'	'	'
Current assets	'	'	'	'
Cash and cash equivalents	22,211	42,749	47,103	70,860
Accounts receivable, net	1,282	1,822	'	'
Accounts receivable from consolidated subsidiaries	34,246	42,865	'	'
Inventories, net	0	'	'	'
Prepaid expenses and other current assets	15,252	15,200	'	'
Prepaid taxes	26,440	27,487	'	'
Deferred tax assets	20,178	20,218	'	'
Assets held for sale	2,900	1,669	'	'
Total current assets	122,509	152,010	'	'
Property, plant and equipment, net	2,787	14,189	'	'
Goodwill	0	'	'	'
Intangibles assets, net	0	'	'	'
Investments in affiliates	5,557,650	5,489,676	'	'
Deferred tax assets	33,281	35,877	'	'
Notes receivable and other amounts due from consolidated subsidiaries	1,240,228	1,049,344	'	'
Other assets	24,618	24,574	'	'
Total assets	6,981,073	6,765,670	'	'
Current liabilities	'	'	'	'
Current borrowings	354,561	351,587	'	'
Accounts payable	3,233	2,194	'	'
Accounts payable to consolidated subsidiaries	2,629,161	2,644,296	'	'
Accrued expenses	15,064	15,569	'	'
Current portion of contingent consideration	0	'	'	'
Payroll and benefit-related liabilities	14,504	15,976	'	'
Accrued interest	9,061	8,720	'	'
Income taxes payable	0	'	'	'
Other current liabilities	493	9,646	'	'
Total current liabilities	3,026,077	3,047,988	'	'
Long-term borrowings	930,000	930,000	'	'
Deferred tax liabilities	0	'	'	'
Pension and postretirement benefit liabilities	53,955	57,406	'	'
Noncurrent liability for uncertain tax provisions	11,962	11,389	'	'
Notes payable and other amounts due from consolidated subsidiaries	996,004	785,476	'	'
Other liabilities	20,589	19,884	'	'
Total liabilities	5,038,587	4,852,143	'	'
Total common shareholders' equity	1,942,486	1,913,527	'	'
Noncontrolling interest	0	'	'	'
Total equity	1,942,486	1,913,527	'	'
Total liabilities and equity	6,981,073	6,765,670	'	'
Guarantor Subsidiaries	'	'	'	'
Current assets	'	'	'	'
Cash and cash equivalents	5,513	14,500	'	1,989
Accounts receivable, net	8,528	10,948	'	'
Accounts receivable from consolidated subsidiaries	2,621,175	2,623,314	'	'
Inventories, net	215,672	211,165	'	'
Prepaid expenses and other current assets	6,542	6,870	'	'
Prepaid taxes	0	'	'	'
Deferred tax assets	20,346	22,472	'	'
Assets held for sale	3,504	3,503	'	'
Total current assets	2,881,280	2,892,772	'	'
Property, plant and equipment, net	198,893	188,455	'	'
Goodwill	797,671	797,671	'	'
Intangibles assets, net	949,082	962,243	'	'
Investments in affiliates	1,533,234	1,478,429	'	'
Deferred tax assets	0	'	'	'
Notes receivable and other amounts due from consolidated subsidiaries	1,543,569	873,105	'	'
Other assets	7,485	7,447	'	'
Total assets	7,911,214	7,200,122	'	'
Current liabilities	'	'	'	'
Current borrowings	0	'	'	'
Accounts payable	42,935	45,802	'	'
Accounts payable to consolidated subsidiaries	144,414	147,957	'	'
Accrued expenses	19,821	21,120	'	'
Current portion of contingent consideration	1,658	4,131	'	'
Payroll and benefit-related liabilities	12,715	21,818	'	'
Accrued interest	0	'	'	'
Income taxes payable	0	'	'	'
Other current liabilities	18,465	7,517	'	'
Total current liabilities	240,008	248,345	'	'
Long-term borrowings	0	'	'	'
Deferred tax liabilities	497,911	496,228	'	'
Pension and postretirement benefit liabilities	33,642	33,777	'	'
Noncurrent liability for uncertain tax provisions	17,313	17,241	'	'
Notes payable and other amounts due from consolidated subsidiaries	1,605,977	957,451	'	'
Other liabilities	16,312	16,221	'	'
Total liabilities	2,411,163	1,769,263	'	'
Total common shareholders' equity	5,500,051	5,430,859	'	'
Noncontrolling interest	0	'	'	'
Total equity	5,500,051	5,430,859	'	'
Total liabilities and equity	7,911,214	7,200,122	'	'
Non-Guarantor Subsidiaries	'	'	'	'
Current assets	'	'	'	'
Cash and cash equivalents	393,925	374,735	259,451	264,190
Accounts receivable, net	282,435	279,048	'	'
Accounts receivable from consolidated subsidiaries	217,359	214,469	'	'
Inventories, net	149,244	138,165	'	'
Prepaid expenses and other current assets	25,749	17,740	'	'
Prepaid taxes	16,030	9,017	'	'
Deferred tax assets	11,463	10,230	'	'
Assets held for sale	5,310	5,256	'	'
Total current assets	1,101,515	1,048,660	'	'
Property, plant and equipment, net	126,999	123,256	'	'
Goodwill	574,387	556,532	'	'
Intangibles assets, net	301,451	293,354	'	'
Investments in affiliates	21,342	21,382	'	'
Deferred tax assets	4,485	4,476	'	'
Notes receivable and other amounts due from consolidated subsidiaries	1,149,117	14,169	'	'
Other assets	35,686	38,074	'	'
Total assets	3,314,982	2,099,903	'	'
Current liabilities	'	'	'	'
Current borrowings	4,700	4,700	'	'
Accounts payable	24,926	23,971	'	'
Accounts payable to consolidated subsidiaries	99,205	88,395	'	'
Accrued expenses	44,570	38,179	'	'
Current portion of contingent consideration	0	'	'	'
Payroll and benefit-related liabilities	32,966	35,296	'	'
Accrued interest	5	5	'	'
Income taxes payable	27,451	23,821	'	'
Other current liabilities	4,683	5,072	'	'
Total current liabilities	238,506	219,439	'	'
Long-term borrowings	0	'	'	'
Deferred tax liabilities	62,356	57,896	'	'
Pension and postretirement benefit liabilities	18,495	18,315	'	'
Noncurrent liability for uncertain tax provisions	26,681	26,522	'	'
Notes payable and other amounts due from consolidated subsidiaries	1,336,512	197,173	'	'
Other liabilities	12,706	12,401	'	'
Total liabilities	1,695,256	531,746	'	'
Total common shareholders' equity	1,616,985	1,565,668	'	'
Noncontrolling interest	2,741	2,489	'	'
Total equity	1,619,726	1,568,157	'	'
Total liabilities and equity	$3,314,982	$2,099,903	'	'

Condensed_Consolidating_Statem1

Condensed Consolidating Statements of Cash Flows (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 30, 2014	Mar. 31, 2013
Condensed Cash Flow Statements Captions [Line Items]	'	'
Net cash (used in) provided by operating activities from continuing operations	$33,600	$5,264
Cash Flows from Investing Activities of Continuing Operations:	'	'
Expenditures for property, plant and equipment	-12,109	-15,635
Proceeds from sales of assets and investments	1,669	'
Payments for businesses and intangibles acquired, net of cash acquired	-28,991	1,500
Investments in affiliates	-60	'
Net cash provided by (used in) investing activities from continuing operations	-39,491	-14,135
Cash Flows from Financing Activities of Continuing Operations:	'	'
Proceeds and tax benefits from share based compensation plans	8,641	5,155
Debt issuance and amendment fees	-90	'
Dividends	-14,051	-13,964
Intercompany transactions	0	'
Payments for contingent consideration	'	-7,179
Intercompany dividends paid	'	'
Net cash provided by (used in) financing activities from continuing operations	-5,500	-15,988
Cash Flows from Discontinued Operations:	'	'
Net cash used in operating activities	-1,167	-629
Net cash used in discontinued operations	-1,167	-629
Effect of exchange rate changes on cash and cash equivalents	2,223	-4,997
Net (decrease) increase in cash and cash equivalents	-10,335	-30,485
Cash and cash equivalents at the beginning of the period	431,984	337,039
Cash and cash equivalents at the end of the period	421,649	306,554
Consolidation, Eliminations	'	'
Condensed Cash Flow Statements Captions [Line Items]	'	'
Net cash (used in) provided by operating activities from continuing operations	0	-47,541
Cash Flows from Investing Activities of Continuing Operations:	'	'
Expenditures for property, plant and equipment	0	'
Proceeds from sales of assets and investments	0	'
Payments for businesses and intangibles acquired, net of cash acquired	0	'
Investments in affiliates	0	'
Net cash provided by (used in) investing activities from continuing operations	0	'
Cash Flows from Financing Activities of Continuing Operations:	'	'
Proceeds and tax benefits from share based compensation plans	0	'
Debt issuance and amendment fees	0	'
Dividends	0	'
Intercompany transactions	0	'
Intercompany dividends paid	'	47,541
Net cash provided by (used in) financing activities from continuing operations	0	47,541
Cash Flows from Discontinued Operations:	'	'
Net cash used in operating activities	0	'
Net cash used in discontinued operations	0	'
Effect of exchange rate changes on cash and cash equivalents	0	'
Net (decrease) increase in cash and cash equivalents	0	'
Cash and cash equivalents at the beginning of the period	0	'
Cash and cash equivalents at the end of the period	0	'
Parent Company	'	'
Condensed Cash Flow Statements Captions [Line Items]	'	'
Net cash (used in) provided by operating activities from continuing operations	-30,503	-37,035
Cash Flows from Investing Activities of Continuing Operations:	'	'
Expenditures for property, plant and equipment	-753	-155
Proceeds from sales of assets and investments	1,669	'
Payments for businesses and intangibles acquired, net of cash acquired	0	'
Investments in affiliates	-60	'
Net cash provided by (used in) investing activities from continuing operations	856	-155
Cash Flows from Financing Activities of Continuing Operations:	'	'
Proceeds and tax benefits from share based compensation plans	8,641	5,155
Debt issuance and amendment fees	-90	'
Dividends	-14,051	-13,964
Intercompany transactions	15,776	22,271
Intercompany dividends paid	'	'
Net cash provided by (used in) financing activities from continuing operations	10,276	13,462
Cash Flows from Discontinued Operations:	'	'
Net cash used in operating activities	-1,167	-29
Net cash used in discontinued operations	-1,167	-29
Effect of exchange rate changes on cash and cash equivalents	0	'
Net (decrease) increase in cash and cash equivalents	-20,538	-23,757
Cash and cash equivalents at the beginning of the period	42,749	70,860
Cash and cash equivalents at the end of the period	22,211	47,103
Guarantor Subsidiaries	'	'
Condensed Cash Flow Statements Captions [Line Items]	'	'
Net cash (used in) provided by operating activities from continuing operations	24,438	64,415
Cash Flows from Investing Activities of Continuing Operations:	'	'
Expenditures for property, plant and equipment	-4,823	-12,129
Proceeds from sales of assets and investments	0	'
Payments for businesses and intangibles acquired, net of cash acquired	0	1,500
Investments in affiliates	0	'
Net cash provided by (used in) investing activities from continuing operations	-4,823	-10,629
Cash Flows from Financing Activities of Continuing Operations:	'	'
Proceeds and tax benefits from share based compensation plans	0	'
Debt issuance and amendment fees	0	'
Dividends	0	'
Intercompany transactions	-28,602	-32,594
Payments for contingent consideration	'	-5,781
Intercompany dividends paid	'	-17,400
Net cash provided by (used in) financing activities from continuing operations	-28,602	-55,775
Cash Flows from Discontinued Operations:	'	'
Net cash used in operating activities	0	'
Net cash used in discontinued operations	0	'
Effect of exchange rate changes on cash and cash equivalents	0	'
Net (decrease) increase in cash and cash equivalents	-8,987	-1,989
Cash and cash equivalents at the beginning of the period	14,500	1,989
Cash and cash equivalents at the end of the period	5,513	'
Non-Guarantor Subsidiaries	'	'
Condensed Cash Flow Statements Captions [Line Items]	'	'
Net cash (used in) provided by operating activities from continuing operations	39,665	25,425
Cash Flows from Investing Activities of Continuing Operations:	'	'
Expenditures for property, plant and equipment	-6,533	-3,351
Proceeds from sales of assets and investments	0	'
Payments for businesses and intangibles acquired, net of cash acquired	-28,991	'
Investments in affiliates	0	'
Net cash provided by (used in) investing activities from continuing operations	-35,524	-3,351
Cash Flows from Financing Activities of Continuing Operations:	'	'
Proceeds and tax benefits from share based compensation plans	0	'
Debt issuance and amendment fees	0	'
Dividends	0	'
Intercompany transactions	12,826	10,323
Payments for contingent consideration	'	-1,398
Intercompany dividends paid	'	-30,141
Net cash provided by (used in) financing activities from continuing operations	12,826	-21,216
Cash Flows from Discontinued Operations:	'	'
Net cash used in operating activities	0	-600
Net cash used in discontinued operations	0	-600
Effect of exchange rate changes on cash and cash equivalents	2,223	-4,997
Net (decrease) increase in cash and cash equivalents	19,190	-4,739
Cash and cash equivalents at the beginning of the period	374,735	264,190
Cash and cash equivalents at the end of the period	$393,925	$259,451

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (Subsequent Event, USD $)	0 Months Ended
In Millions, unless otherwise specified	Apr. 28, 2014
Subsequent Event [Line Items]	'
Cash repatriated from Non-United States subsidiaries	$230
Revolver Borrowings Under Senior Credit Facility	'
Subsequent Event [Line Items]	'
Repayments of Debt	235
Minimum	'
Subsequent Event [Line Items]	'
Expected restructuring charges	42
Maximum	'
Subsequent Event [Line Items]	'
Expected restructuring charges	53
2014 Restructuring Plan | Minimum	'
Subsequent Event [Line Items]	'
Expected restructuring charges	42
Expected restructuring charges which will result cash outlay	32
2014 Restructuring Plan | Maximum	'
Subsequent Event [Line Items]	'
Expected restructuring charges	53
Expected restructuring charges which will result cash outlay	$40

Summary_of_Current_Cost_Estima

Summary of Current Cost Estimates by Major Type of Cost Associated with Plan (Detail) (Subsequent Event, USD $)	0 Months Ended
In Millions, unless otherwise specified	Apr. 28, 2014
Minimum	'
Subsequent Event [Line Items]	'
Expected restructuring charges	$42
Maximum	'
Subsequent Event [Line Items]	'
Expected restructuring charges	53
Termination Benefits | Minimum	'
Subsequent Event [Line Items]	'
Expected restructuring charges	12
Termination Benefits | Maximum	'
Subsequent Event [Line Items]	'
Expected restructuring charges	15
Facility Closure Costs | Minimum	'
Subsequent Event [Line Items]	'
Expected restructuring charges	2	[1]
Facility Closure Costs | Maximum	'
Subsequent Event [Line Items]	'
Expected restructuring charges	5	[1]
Accelerated depreciation charges | Minimum	'
Subsequent Event [Line Items]	'
Expected restructuring charges	10
Accelerated depreciation charges | Maximum	'
Subsequent Event [Line Items]	'
Expected restructuring charges	12
Other | Minimum	'
Subsequent Event [Line Items]	'
Expected restructuring charges	18	[2]
Other | Maximum	'
Subsequent Event [Line Items]	'
Expected restructuring charges	$21	[2]
[1]	Includes costs to transfer product lines among facilities and outplacement and employee relocation costs.
[2]	Consists of other costs directly related to the Plan, including project management, legal and other regulatory costs.